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Role of Chaperonin CCT in G-protein Biosynthesis 
 
Catherine A. Woodard 
 
 
Chaperonins  are  ubiquitous  molecular  chaperones  that  are  found  in  all  animal  kingdoms.    They  all  share  a  
common  structure  and  function  to  assist  the  folding  of  other  proteins.    All  chaperonins  consist  of  two  stacked  rings,  which  
come  together  to  form  a  central  cavity  where  folding  can  take  place (1).    The  eukaryotic  cytosolic  chaperonin  containing  
TCP1  (CCT)  is  a  member  of  the  group  II  chaperonins,  which  are  defined  as  having  octameric  or  nonameric  rings  
composed  of  more  than  one  type  of  subunit (2).    CCT  is  unique  because  it  is  composed  of  eight  different  subunits  (CCTα,  
β,  γ,  δ,  ε,  ζ,  η,  θ) (2),  which  also  makes  it  the  most  complex  of  the  group  II  chaperonins.    The  molecular  diversity  in  the  
subunit  composition  of  CCT  gives  rise  to  a  more  specialized  role  in  protein  folding  than  the  general,  nonspecific  
mechanism  that  is  seen  in  other  chaperonins.    Substrate  recognition  is  accomplished  by  the  apical  domains,  which  are  
highly  flexible  and  undergo  large  conformational  changes  during  the  functional  cycle.    In  the  open  conformation,  the  
apical  domains  allow  substrates  to  enter  into  central  cavity.  Nucleotide  binding  at  the  equatorial  domain  occurs  once  
substrate  is  bound  and  ATP  hydrolysis  triggers  the  conversion  from  the  open  to  the  closed  conformation (1).  The  exact  
mechanism  has  not  been  clearly  defined,  but  is  thought  to  involve  a  set  of  sequential,  hierarchical  steps.  
CCT  is  an  essential  part  of  eukaryotic  cell  function,  and  it  has  been  estimated  that  it  folds  up  to  10%  of  newly  
synthesized  cytosolic  proteins (3).    Some  of  the  proteins  that  have  been  shown  to  depend  on  CCT  for  their  biogenesis  
include  cytoskeletal  proteins  (α-­‐‑,  and  β-­‐‑actin,  α-­‐‑,  β-­‐‑,  and  γ-­‐‑tubulin),  histone  deacetylases  (HDAC3,  Set3p,  and  Hos2p),  cell  
cycle  regulators  (Cdc20p,  and  Cdc55p),  and  proteins  possessing  the  seven-­‐‑bladed  β-­‐‑propeller  WD40  domain,  including  
the  β-­‐‑subunit  of  the  heterotrimeric  guanine  nucleotide-­‐‑binding  protein  (G-­‐‑protein)  complex (4, 5).  Heterotrimeric  G  
proteins  are  a  highly  conserved  group  of  molecules  involved  in  a  great  number  of  signaling  processes.  They  are  
composed  of  three  subunits  (α-­‐‑,  β-­‐‑,  and  γ),  which  are  bound  together  in  the  inactive  form.    In  this  heterotrimeric  state,  
guanosine  di-­‐‑phosphate  (GDP)  is  bound  to  the  G  α-­‐‑subunit.  Upon  activation,  the  α-­‐‑subunit  exchanges  GDP  for  guanosine  
tri-­‐‑phosphate  (GTP).    This  exchange  triggers  Gβγ  to  dissociate  from  Gα  and  both  Gα-­‐‑GTP  and  Gβγ  are  then  free  to  
activate  downstream  effectors.  This  form  of  signal  transduction  is  so  common  that  G-­‐‑proteins  regulate  or  modulate  nearly  
every  cellular  and  physiological  process.    Because  it  is  so  critical  for  normal  cellular  function,  dysregulation  of  G-­‐‑protein  
signaling  is  associated  with  many  human  diseases (6)  and  more  than  half  of  the  current  pharmaceutical  therapies  target  a  
component  of  the  G-­‐‑protein  pathway (7).  While  much  is  known  about  the  signal  transduction,  far  less  is  known  about  the  
biogenesis  and  assembly  of  G-­‐‑proteins.    
The  overall  objective  of  my  research  has  been  to  elucidate  the  mechanisms  of  the  chaperonin  containing  Tailless  
Complex  Polypeptide  1  (CCT)  with  respect  to  heterotrimeric  guanine  nucleotide-­‐‑binding  protein  (G  protein)  signaling.    
The  CCT  co-­‐‑factor,  phosducin-­‐‑like  protein  (PhLP)  is  required  for  Gβ  biosynthesis,  and  therefore  its  mechanism  is  critical  
for  our  understanding  of  this  process.    In  the  first  chapter  of  my  thesis,  I  take  a  structure-­‐‑based  approach  to  investigate  
the  interaction  between  PhLP  and  Gβ.    Currently  there  are  no  available  structures  of  this  complex,  nor  is  there  a  single  
published  structure  of  PhLP.    Therefore,  I  used  a  homology  modeling  approach  to  generate  the  first  known  3D  structure  
of  PhLP.    Then  in  order  to  gain  insight  into  this  interaction,  I  docked  PhLP  to  the  Gβγ  and  compared  it  to  the  crystal  
structure  of  phosducin  (Pdc),  a  closely  related  protein  that  also  forms  a  complex  with  Gβγ.    The  second  chapter  is  centered  
on  a  truncated  splice  isoform  of  PhLP,  referred  to  as  PhLPSHORT  (PhLPs),  which  has  been  shown  to  be  a  potent  inhibitor  of  
CCT.    A  recent  paper  published  by  my  lab  showed  that  PhLPs  expression  led  to  a  decrease  in  α-­‐‑,  β-­‐‑,  and  γ-­‐‑subunits  of  the  
G-­‐‑protein  transducin  at  the  protein  level.    Later  experiments  showed  that  this  decrease  occurred  at  the  mRNA  level  as  
well.    While  the  decrease  in  Gβ  and  Gγ  wasn’t  surprising,  the  decrease  in  Gα  was  unexpected  since  it  is  not  a  known  
substrate  of  CCT.    In  order  to  find  a  connection  between  CCT  and  Gα,  I  looked  for  any  perturbations  of  gene  expression  
that  occurred  in  transgenic  mice  constitutively  expressing  PhLPs  using  microarray  results.      Furthermore,  because  these  
mice  express  PhLPs  at  an  early  age  I  repeated  these  experiments  in  inducible  transgenic  mouse  lines  that  we  developed  to  
express  PhLPs  in  adult  mice.    Taken  together,  my  research  provides  additional  data  to  refine  the  mechanism  of  Gβ  
biosynthesis  and  suggests  that  there  is  an  additional  level  of  regulatory  control  over  G-­‐‑proteins  that  connects  the  
expression  of  all  three  subunits.  
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Although  the  eukaryotic  cytosolic  chaperonin  containing  TCP1  (CCT)  is  the  most  complex  of  the  group  II  
chaperonins,  it  is  evolutionarily  conserved  and  found  in  all  eukaryotes (2).  Figure  1  shows  CCT’s  subunits  each  with  a  
different  color  from  a  top  view  (Figure  1A),  and  a  side  view  (Figure  1B  &  C).    The  structure  of  CCT  remained  unresolved  
for  many  years  due  to  instability  of  the  complex.    Early  cryo-­‐‑EM  experiments  demonstrated  that  the  two  hetero-­‐‑octameric  
rings  of  CCT  formed  the  typical  cylindrical  shape,  but  the  resolution  was  not  sufficient  to  observe  secondary  structures 
(8).    An  early  model  of  CCT  shows  the  different  domains  form  the  inner  cavity,  but  incorrectly  places  the  hetero-­‐‑octameric  
rings  stacked  directly  on  top  of  one  another  (Figure  1D).  More  recent  models  have  been  refined  using  data  from  cryo-­‐‑EM  
and  X-­‐‑ray  crystallography  studies  at  greater  resolution  to  show  an  inter-­‐‑ring  misalignment  that  relates  the  upper  and  
lower  ring  by  a  pseudo-­‐‑two-­‐‑fold  symmetry (1)(Figure  1E).    Figure  1E  also  illustrates  two  tubulin  substrate  molecules  in  
the  inner  cavity  (magenta  and  lime  green).  The  molecular  diversity  in  the  subunit  composition  of  CCT  gives  rise  to  a  more  
specialized  role  in  protein  folding  than  the  general,  nonspecific  mechanism  that  is  seen  in  other  chaperonins.    Substrate  
recognition  is  accomplished  by  the  apical  domains  (Figure  1D),  which  are  highly  flexible  and  undergo  large  
conformational  changes  during  the  functional  cycle.    In  the  open  conformation,  the  apical  domains  allow  substrates  to  
enter  into  central  cavity.  Nucleotide  binding  at  the  equatorial  domain  occurs  once  substrate  is  bound  and  ATP  hydrolysis  
triggers  the  conversion  from  the  open  to  the  closed  conformation (1).  The  exact  mechanism  has  not  been  clearly  defined,  
but  is  thought  to  involve  a  set  of  sequential,  hierarchical  steps.    
It  has  been  estimated  that  CCT  may  fold  up  to  10%  of  newly  synthesized  cytosolic  proteins (3),  so  it  plays  an  
essential  role  in  eukaryotic  cellular  function.  Because  CCT  substrates  are  very  diverse  in  function  as  well  as  structure,  they  
cannot  be  predicted  by  homology  alone (5).    Some  of  the  proteins  that  have  been  shown  to  depend  on  CCT  for  their  
biogenesis  include  cytoskeletal  proteins  (α-­‐‑,  and  β-­‐‑actin,  α-­‐‑,  β-­‐‑,  and  γ-­‐‑tubulin),  histone  deacetylases  (HDAC3,  Set3p,  and  
Hos2p),  cell  cycle  regulators  (Cdc20p,  and  Cdc55p),  and  proteins  possessing  a  seven-­‐‑bladed  β-­‐‑propeller  (WD40  repeat  




G-­‐‑proteins  are  a  highly  conserved  group  of  molecules  involved  in  a  great  number  of  signaling  processes.  They  are  
composed  of  α-­‐‑,  β-­‐‑,  and  γ-­‐‑subunits,  which  are  bound  together  in  the  inactive  form.    In  this  heterotrimeric  state,  guanosine  
di-­‐‑phosphate  (GDP)  is  bound  to  the  G  α-­‐‑subunit  (Gα).  Upon  activation,  the  Gα  exchanges  GDP  for  guanosine  tri-­‐‑
phosphate  (GTP).    This  exchange  triggers  Gβγ  to  dissociate  from  Gα  and  both  Gα-­‐‑GTP  and  Gβγ  are  then  free  to  activate  
downstream  effectors.    While  much  is  known  about  the  signal  transduction,  far  less  is  known  about  the  biogenesis  and  
assembly  of  G-­‐‑proteins.  Currently  it  is  known  that  these  proteins  come  from  several  distinct  genes.    In  humans,  16  genes  
code  for  Gα,  12  genes  code  for  Gγ,  and  5  genes  code  for  Gβ.    Figure  2  shows  a  model  of  Gβ  biogenesis  and  subsequent  
assembly  into  the  heterotrimeric  G-­‐‑protein  complex  at  the  plasma  membrane.    CCT  folds  nascent  Gβ  with  the  help  of  the  
essential  cofactor,  phosducin-­‐‑like  protein  (PhLP),  but  the  order  of  these  steps  are  not  well  defined.  
PhLP  a  member  of  the  phosducin  (Pdc)  family  of  proteins.  The  Pdc  gene  family  is  divided  into  three  subgroups.    
Subgroup  I  consists  of  Pdc  and  PhLP1,  which  are  both  able  to  bind  Gβγ  subunits  with  high  affinity (12).  PhLP1  is  
ubiquitously  expressed (13)  and  is  considered  to  be  a  modulator  of  Gβγ  function (14)  through  its  interaction  with  CCT.  In  
contrast,  Pdc  expression  is  restricted  to  retinal  photoreceptor  cells  and  the  pineal  gland (10).    Subgroup  II  consists  of  
PhLP2A  and  PhLP2B,  which  were  both  discovered  in  humans,   (15).  In  yeast,  the  PhLP2  ortholog  does  not  bind  Gβγ,  but  
is  essential  for  cell  growth  in  both  the  yeast  Saccharomyces  cerevisiae (16)  and  the  soil  amoebae  Dictyostelium  discoideum (15).    
Subgroup  III  is  comprised  of  only  PhLP3 (15),  which  is  thought  to  participate  in  β-­‐‑tubulin  and  possibly  actin  folding (17),  
but  binds  Gβγ  poorly (16).    While  the  members  of  the  Pdc  gene  family  have  seemingly  unrelated  functions,  one  
commonality  among  PhLP  1–3  is  that  they  are  all  thought  to  participate  in  protein  folding  by  acting  as  co-­‐‑chaperones (12).    
Figure  2.  A  model  of  Gβ  biogenesis  and  assembly  into  the  heterotrimeric  G-­‐‑protein  complex  at  the  plasma  membrane.    1.  
Nascent  Gβ  is  folded  by  CCT  with  the  help  of  the  phosducin-­‐‑like  protein  (PhLP)  co-­‐‑chaperone (9, 10).  2.  All  Gβ  subunits  
irreversibly  associate  with  Gγ  soon  after  biogenesis  and  exist  as  dimers,  with  the  exception  of  the  Gβ5  subunit.    It  is  not  clear  
when,  but  at  some  point  PhLP  dissociates  and  the  Gβγ  dimer  is  formed.    3.  Gγ  becomes  farnesylated  or  geranylgeranylated,  
which  anchors  Gβγ  to  the  membrane,  and  is  then  targeted  to  the  cytoplasmic  surface  of  the  endoplasmic  reticulum  (ER).  4.  
Details  of  Gα  biogenesis  are  still  unclear,  but  it  becomes  either  palmitoylated  or  myristoylated  to  anchor  it  to  the  membrane.  5.  
It  is  speculated  that  Gα  associates  with  Gβγ  at  the  ER  and  6.  the  heterotrimeric  G-­‐‑protein  complex  is  subsequently  trafficked  to  
the  plasma  membrane (11). 
 6 
PhLP1  is  the  most  well  studied  studied  of  this  family.  Cryogenic  Electron  Microscopy  (Cryo-­‐‑EM)  studies  have  shown  that  
PhLP  is  not  a  substrate  of  CCT.    Instead,  PhLP  interacts  with  CCT’s  apical  domains  on  the  top  of  the  complex  without  any  
part  of  its  mass  entering  the  folding  cavity  (Figure  3).    These  studies  have  also  shown  that  PhLP  can  interact  with  CCT  in  
a  one  to  one  ratio  and  can  interact  with  any  of  CCT’s  subunits  to  assume  one  of  two  conformations (18).      
Although  there  has  been  extensive  research  into  G-­‐‑protein  signaling,  there  are  still  many  gaps  in  our  
understanding  of  G-­‐‑protein  biosynthesis.    Because  there  are  currently  there  are  no  available  structures  of  this  complex,  
nor  is  there  a  single  published  structure  of  PhLP  I  have  used  a  homology  modeling  approach  to  generate  the  first  known  
3D  structure  of  PhLP.    The  information  that  is  gained  from  these  structure-­‐‑based  studies  can  be  combined  with  what  is  
known  from  biochemical  studies  in  order  to  gain  isight  into  the  interaction  between  PhLP  and  Gβ.    Using  this  information  
I  can  make  predictions  to  refine  the  mechanism  of  Gβ  biosynthesis.  
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Initially  most  of  the  G-­‐‑protein  research  had  focused  on  Gα,  leaving  Gβγ  largely  ignored.    However,  more  recent  
research  has  indicated  that  because  of  Gβ’s  unique  structure,  it  is  able  to  interact  with  a  wide  variety  of  other  proteins  and  
plays  a  very  important  role  in  cell  signaling.    Structurally,  Gβ  is  a  circular  molecule  composed  of  seven  β-­‐‑propeller  WD40  
repeats  and  belongs  to  the  large  family  of  WD40  proteins (23).    Like  other  WD40  proteins,  Gβγ  is  able  to  interact  with  a  
wide  variety  of  proteins.    X-­‐‑ray  crystallography  of  Gβ  co-­‐‑crystalized  with  its  binding  partners  has  revealed  that  all  of  Gβ’s  
binding  partners  share  a  common  interface  (Figure  4).    A  recent  review  conducted  on  the  structural  interaction  of  Gβγ  
with  its  binding  partners  suggests  that  each  protein  interacts  with  Gβγ  through  a  unique  combination  of  residues  within  
the  common  binding  surface (24).    This  region  of  multi-­‐‑target  recognition  called  a  “hot  spot”,  is  a  region  on  the  protein  
surface  that  is  structurally  flexible  enough  to  
accommodate  multiple  modes  of  binding   (24).    
This  interface  is  also  the  point  of  interaction  
between  Gα  and  Gβγ  (figure  4D).  
Heterotrimeric  G-­‐‑protein  signaling  begins  with  
dissociation  of  Gα-­‐‑GTP  from  the  Gβγ  dimer.    
While  Gα  subunit  signaling  is  terminated  by  
hydrolysis  of  GTP,  Gβγ  signaling  must  be  
terminated  by  re-­‐‑association  with  Gα  subunits  
or  in  a  way  that  blocks  the  binding  surface  of  
Gβ.    The  re-­‐‑association  of  the  G-­‐‑protein  α-­‐‑,  β-­‐‑,  
and  γ-­‐‑subunits  into  the  inactive  heterotrimeric  
G-­‐‑protein  complex  is  a  critical  point  in  the  
regulation  of  overall  G-­‐‑protein  signaling  
activity.      
Phosducin-­‐‑like  protein  (PhLP)  plays  an  
important  role  in  Gβ  biosynthesis,  but  the  
mechanism  is  not  well  understood.    Our  current  
understanding  of  this  process  was  summarized  
by  Willardson  and  Howlett  in  2007  (Figure  5) 
(12).  As  a  nascent  Gβ  emerges,  it  forms  a  
ternary  complex  by  entering  into  the  folding  
cavity  of  CCT  and  binding  to  PhLP  and.    It  is  
not  clear  whether  Gβ  associates  with  PhLP  
before  or  after  entering  CCT,  but  the  interaction  
is  controlled  by  PhLP  because  over-­‐‑expression  
of  PhLP  decreases  the  binding  of  Gβ  to  CCT (25).    In  this  model  it  is  theorized  that  the  purpose  of  PhLP  is  to  pull  the  
folded  Gβ  out  of  CCT  and  direct  it  to  the  membrane  where  it  can  associate  with  Gα.    It  is  also  thought  that  this  
mechanism  is  regulated  by  phosphorylation  of  PhLP.    Phosphorylation  of  residues  S18-­‐‑20  by  casein  kinase  2  (CK2)  is  
predicted  to  destabilize  the  ternary  complex  so  that  PhLP  and  the  folded  Gβ  can  be  released (25).    
Experiments  involving  the  truncated  splice  variant  of  phosducin-­‐‑like  protein  (PhLP),  referred  to  as  PhLPSHORT  
(PhLPs) (19),  have  provided  additional  information  that  seems  to  support  this  mechanism.    Despite  having  a  significantly  
reduced  affinity  for  Gβ (14, 21),  PhLPs  is  still  able  to  inhibit  CCT  in  a  dominant  negative  fashion (20, 25),  
Immunoprecipitation  (IP)  experiments  utilizing  transgenic  mice  expressing  PhLPs-­‐‑FLAG  (Tg+)  in  photoreceptors  indicate  
that  PhLPs  is  still  able  to  interact  with  CCT  (Figure  7A).    The  additional  presence  of  the  transducin  β-­‐‑subunit  (Gβ1)  in  the  
IP  suggests  that  the  trimeric  PhLP(s)-­‐‑CCT-­‐‑Gβ1  complex  forms  but  cannot  separate,  leaving  Gβ  trapped  inside  CCT  (Figure  
7B).    This  supports  Willardson’s  model  because  the  N-­‐‑terminal  residues  that  PhLPs  lacks  contain  the  residues  implicated  












In  order  to  gain  a  better  understanding  of  the  involvement  of  PhLP  in  Gβ  biosynthesis,  I  combined  experimental  
data  with  structural  information.  Using  homology  modeling,  I  was  able  to  construct  a  3-­‐‑dimensional  model  of  PhLP  
based  on  the  crystal  structure  of  the  closely  related  protein  phosducin  (Pdc).    Then  I  docked  the  PhLP  model  to  the  crystal  
structure  of  Gβ1  to  simulate  binding.    By  identifying  the  residues  involved  in  binding  to  Gβ,  binding  to  CCT,  and  
phosphorylation  I  demonstrate  how  PhLP  is  able  to  associate  with  both  CCT  and  Gβ,  and  predict  how  phosphorylation  of  
PhLP  triggers  the  release  of  Gβ.    Ultimately,  this  information  may  determine  CCT’s  role  in  G-­‐‑protein  biosynthesis  through  






Generating  a  3D  structure  of  PhLP  
   In  order  to  gain  a  better  understanding  of  the  role  that  CCT  plays  in  G-­‐‑protein  biosynthesis,  we  must  first  
figure  out  how  the  interaction  between  its  co-­‐‑chaperone,  PhLP,  and  its  substrate,  Gβ.    There  are  currently  no  published  
structures  of  PhLP.    In  order  to  determine  how  PhLP  is  interacting  with  Gβ,  and  to  predict  the  mechanism  of  release  I  
generated  a  3D  structure  of  PhLP  based  on  homology  modeling.    Homology  modeling  is  the  most  accurate  and  widely  
used  method  of  protein  structure  prediction.    It  is  based  on  the  empirical  observation  that  3D  structure  is  the  most  
robustly  conserved  feature  of  homologous  proteins.    Even  when  the  primary  sequence  has  been  altered  by  mutation,  
deletion,  or  insertions,  the  3D  structure  of  evolutionarily  related  proteins  is  largely  preserved.  Building  a  3D  model  of  an  
unknown  “target”  protein  based  on  its  primary  amino  acid  sequence  requires  a  closely  related  protein  with  a  known  3D  
structure  to  act  as  a  “template”.  There  are  different  approaches  to  homology  modeling,  but  they  all  follow  four  basic  
steps;  1)  identify  one  or  more  proteins  to  serve  as  the  3D  template,  2)  sequence-­‐‑structure  alignment  to  line  up  amino  acid  
residues  of  the  target  to  the  corresponding  ones  in  the  
template,  3)  use  the  sequence-­‐‑structure  alignment  to  
generate  a  3D  model  of  the  target  protein,  and  4)  
evaluate  the  model  for  correctness  (Figure  7).    
  The  phosducin  family  of  proteins  is  very  small  
and  the  proteins  are  evolutionarily  conserved  from  
simple  single  cell  eukaryotes  to  higher  order  mammals.  
Fortunately,  the  crystal  structure  of  rat  phosducin  
(Pdc)  has  been  solved (26).    Phosducin  and  PhLP  are  
both  members  of  Subgroup  II  of  the  phosducin  family,  
and  both  proteins  have  a  high  degree  of  similarity.    To  
confirm  that  Pdc  was  the  best  protein  to  use  as  a  
template  for  mouse  PhLP,  the  Position-­‐‑Specific  
Iterative  Basic  Local  Alignment  Search  Tool  (PSI-­‐‑
BLAST)  was  used  via  the  Internet-­‐‑based  PredictProtein  
(www.predictprotein.org)  website.  The  sequence  of  
mouse  PhLP1  has  301  amino  acids  and  rat  Pdc  has  246  
amino  acids.    They  share  65%  similarity  in  primary  
amino  acid  sequence  with  109  identical  and  88  similar  
residues,  making  it  the  best  template  with  a  crystal  
structure.    Two  different  3D  structures  of  rat  Pdc  were  
available  through  the  Protein  Data  Bank  (PDB  =  1B9X,  
and  2TRC),  and  both  were  used  as  template  molecules  
for  homology  modeling.    
Sequence  alignment  and  the  generation  of  a  3D  
model  of  PhLP1  were  accomplished  using  INSIGHTII,  
a  graphical  molecular  modeling  program  developed  by  
Accelrys  Inc.  (formerly  a  product  of  MSI  and  BIOSYM).    
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Using  INSIGHTII,  the  amino  acid  sequence  of  PhLP  was  aligned  to  those  of  the  two  Pdc  templates  based  coordinates  
obtained  from  their  crystal  structures.  In  order  to  confirm  the  sequence  alignment  and  to  determine  how  similar  the  
structure  of  PhLP  will  be  to  Pdc,  PredictProtein  was  used  to  predict  the  secondary  structure,  solvent  accessibility  and  
membrane  helices.    PredictProtein  makes  these  predictions  by  combining  results  of  the  PHD  and  PROF  servers  in  order  to  
visually  represent  the  likelihood  of  beta  sheet  or  alpha  helical  secondary  structures,  disordered  regions,  and  solvent  
accessibility  occurring  along  the  primary  amino  acid  sequence  (Figure  8).    Secondary  structure  prediction  was  done  for  
PhLP  and  Pdc  individually  and  then  compared  back  to  the  sequence-­‐‑structure  alignment  generated  by  INSIGHTII  (Figure  
10).    PredicProtein  accurately  predicted  the  secondary  structural  features  of  Pdc.    Based  on  these  prediction,  the  C-­‐‑
terminal  domain  of  PhLP  is  very  similar  to  Pdc  but  there  were  two  notable  differences  in  the  N-­‐‑terminus.    First,  in  PhLP  
Helix  2  is  predicted  to  be  closer  to  Helix  1  while  in  Pdc  Helix  2  is  adjacent  to  Helix  3.    Secondly,  the  region  of  the  N-­‐‑
terminus  before  Helix  1  is  much  longer  in  PhLP  and  is  predicted  to  be  disordered  and  solvent  accessible.      
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Generation  of  a  3D  PhLP  model  was  accomplished  using  the  CONSENSUS  module  of  INSIGHTII,  using  distance  
constraints  derived  from  the  reference  protein  structures  (Figure  11).  Superimposing  the  PhLP  model  onto  the  Pdc  
structure  indicates  the  high  degree  of  similarity  between  the  two  structures.    In  figure  11A  Pdc  is  modeled  by  a  light  blue  
ribbon  with  the  flexible  N-­‐‑terminus  and  the  C-­‐‑terminal  thioredoxin  domain  indicated.    The  C-­‐‑terminus  of  Pdc  is  rigid,  but  
the  N-­‐‑terminus,  which  is  composed  of  3  α-­‐‑helices  (H1,  H2,  H3)  is  very  flexible.  Figure  11  B&C  shows  Pdc  modeled  by  a  
dark  blue  ribbon  and  PhLP  modeled  by  a  green  ribbon.    The  C-­‐‑terminal  thioredoxin  domain  is  almost  perfectly  
superimposed  but,  with  the  exception  of  H3,  the  N-­‐‑terminal  domain  shows  significant  differences.    Figure  11D  shows  the  
structure  of  PhLP  in  green  with  residues  involved  in  Gβ  binding  predicted  by  homology  to  Pdc  shown  in  light  blue,  
residues  involved  in  CCT  binding  in  white,  and  phosphorylation  sites  in  red.    The  N-­‐‑  and  C-­‐‑terminus  are  longer  than  that  
of  Pdc,  and  are  shown  in  figure  11  C&D  to  extend  out  away  from  the  rest  of  the  molecule.    Figure  11  C&D  suggests  that  
portions  of  the  N-­‐‑terminus  of  PhLP  are  less  disordered  and  exposed  to  solvent,  but  no  conclusions  can  be  drawn  since  
there  is  no  template  for  structure  prediction.  The  red  arrows  in  figure  11B&C  point  to  the  region  on  helix-­‐‑1  that  is  critical  
for  Gβ  binding.  These  residues  are  conserved  between  PhLP  and  Pdc  but  since  figure  11B  indicates  that  they  are  not  
superimposed,  it  is  likely  that  there  are  differences  in  Gβ  binding.  The  white  arrows  in  figure  11B,C,  and  D  point  to  a  
flexible  loop  that  may  be  implicated  in  triggering  the  release  of  Gβ.    The  residues  on  PhLP  that  are  involved  in  binding  to  
CCT  are  shown  in  white  in  figure  11D.    The  flexible  loop  on  the  N-­‐‑terminus  of  PhLP  that  is  involved  in  CCT  binding  is  
not  present  in  Pdc,  which  explains  why  phosducin  is  unable  to  bind  CCT.    Note  that  in  Figure  11A  only  one  α-­‐‑helix  
connects  the  N-­‐‑terminal  domain  of  Pdc  to  the  C-­‐‑terminal  domain,  while  in  figure  11C  PhLP  has  two  connections  (pink  
arrows).    H3  connects  the  N-­‐‑  and  C-­‐‑terminal  domains  of  both  PhLP  and  Pdc.    The  second  connection  between  the  N-­‐‑  and  
C-­‐‑terminus  of  PhLP  is  formed  by  residues  on  the  N-­‐‑terminus  prior  to  H1.    This  suggests  that  PhLP  is  much  less  flexible  
than  Pdc.  
In  order  to  determine  how  PhLP  might  interact  with  Gβ,  I  compared  my  model  to  the  crystal  structure  of  the  Pdc-­‐‑
Gβ1γ1  complex  (PDB  =  2TRC).    Initially,  PhLP  simply  replaces  Pdc  in  the  Pdc-­‐‑Gβ1γ1  complex  to  highlight  the  differences  
between  the  two  proteins  with  respect  to  Gβ  binding  (Figure  12).    Gβ1γ1  is  shown  in  yellow,  Pdc  is  shown  in  light  blue,  
and  PhLP  is  shown  in  green.    In  Figure  12  A&B,  Pdc  makes  three  points  of  contact  with  Gβ1γ1.    H1  is  the  most  critical  for  
binding,  and  H3  as  well  the  residues  on  the  C-­‐‑terminal  domain  help  to  stabilize  the  complex.    In  comparison,  PhLP  seems  
to  wrap  around  Gβ1γ1.    In  figure  12D  the  residues  1-­‐‑83  of  PhLP  are  colored  in  brown  to  illustrate  the  residues  that  are  
absent  in  PhLPs.    These  structures  clearly  indicate  that  PhLP  does  not  interact  with  Gβ1γ1  in  the  same  way  as  Pdc  because  
the  N-­‐‑terminus  is  intertwined  with  Gβ.    The  red  arrows  in  figures  12A&C  indicate  that  the  binding  of  Gβ  to  H1  of  Pdc  and  
PhLP  may  differ,  which  may  affect  the  overall  structure.  In  figures  12  C&D  the  residues  of  PhLP  that  interact  with  CCT  
are  shown  again  in  white,  the  residues  that  contact  Gβ  are  in  light  blue,  and  residues  1-­‐‑83  that  are  removed  in  PhLPs  are  
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shown  in  brown.    The  white  arrow  in  figure  12C&D  points  to  where  the  loop  between  H2  and  H3  of  PhLP  overlaps  with  






























   Despite  the  similarity  between  phosducin  and  PhLP  there  are  subtle  differences  in  their  structure.    By  combining  
the  information  that  we  have  gathered  from  homology  modeling  with  biochemical  data  we  can  speculate  about  PhLP’s  
function  in  three  different  areas.  First,  these  results  help  to  explain  how  PhLP  and  PhLPs  are  both  able  to  interact  with  
CCT  and  Gβ  simultaneously.    The  3D  model  that  I  generated  of  PhLP  shows  that  this  is  possible  because  the  binding  sites  
are  distinct.    Furthermore,  the  mechanism  of  CCT  inhibition  by  PhLPs  that  was  proposed  by  our  lab  (Figure  6)  is  
supported  because  neither  the  CCT  nor  the  Gβ  binding  sites  are  perturbed  in  PhLPs.    Second,  they  reveal  important  
information  about  the  interaction  between  PhLP  and  Gβ  that  is  suggestive  of  its  role  in  G-­‐‑protein  biosynthesis.      
The  mechanism  of  Gβ  biosynthesis  proposed  initially  proposed  by  Georgi  Lukov  and  Barry  Willardson  in  2004  
initially  suggested  that  PhLP  directly  interacts  will  nascent  Gβ  and  this  interaction  is  stabilized  by  CK2  phosphorylation  
of  PhLP (22).    This  mechanism  was  later  refined  by  Barry  Willardson  and  Alyson  Howlett  in  2007  suggesting  that  nascent  
Gβ  first  binds  to  CCT,  which  then  recruits  PhLP (12)(Figure  4).    In  this  later  model,  CK2  phosphorylation  functions  to  
release  Gβ  from  CCT.    The  PhLP-­‐‑Gβ  complex  then  binds  Gγ  forming  the  PhLP-­‐‑Gβγ  complex.    Finally,  Gα  replaces  PhLP  to  
form  the  heterotrimeric  G-­‐‑protein  complex  at  the  membrane.    The  first  issue  that  remains  to  be  resolved  in  this  model  
pertains  to  the  purpose  of  PhLP.  Is  PhLP  required  for  the  folding  of  Gβ  by  PhLP,  to  prevent  Gβ  from  being  released  from  
CCT  before  it  is  properly  folded,  to  stabilize  the  folded  Gβ  until  it  can  be  stabilized  by  Gγ,  or  any  combination  of  those  
roles?    The  second  issue  is  that  although  the  evidence  of  CK2  phosphorylation  causing  release  of  PhLP-­‐‑Gβ  from  CCT  is  
well  supported (25),  the  mechanism  by  which  Gβ  is  released  by  PhLP  is  still  unclear.      
Based  on  the  3D  model  that  I  generated  of  PhLP  I  have  come  up  with  a  revised  mechanism  of  PhLP’s  
involvement  in  G-­‐‑protein  biosynthesis  (Figure  12).    1.  Nascent  Gβ  enters  the  folding  cavity  after  it  is  translated.    PhLP  
does  not  require  Gβ  to  bind  CCT (18).    I  believe  that  the  first  50  amino  acids  in  the  long  unstructured  N-­‐‑terminus  of  PhLP  
may  help  to  weaken  the  interaction  between  PhLP  and  CCT.    However,  this  is  purely  speculative  because  the  structure  of  
this  region  could  not  be  determined.    2.  Once  Gβ  enters  the  inner  chamber  of  CCT  it  becomes  partially  folded,  and  3.  PhLP  
will  be  able  to  bind  with  higher  affinity  because  there  are  more  points  of  contact.    I  predict  that  the  long  unstructured  N-­‐‑
terminus  of  PhLP  pulls  Gβ  out  of  CCT  after  its  folded.    When  PhLP  binds  to  CCT  and  Gβ  to  form  the  tertiary  complex,  
this  strand  becomes  wedged  in  between  Gβ  and  the  C-­‐‑terminal  thioredoxin  domain  of  PhLP,  which  has  a  net  charge  of  -­‐‑
19.  Furthermore,  I  predict  that  when  H1  of  PhLP  binds  to  Gβ  it  causes  the  N-­‐‑terminal  strand  to  rotate,  exposing  residues  
S18-­‐‑20.  4.  When  these  residues  becomes  phosphorylated  by  CK2  the  charge  repulsion  causes  PhLP’s  N-­‐‑terminal  strand  to  
move  away  from  the  C-­‐‑terminal  domain,  6.  effectively  prying  Gβ  out  of  CCT’s  inner  chamber.      
   I  have  also  been  able  to  make  a  prediction  as  to  how  and  when  Gβ  is  released  from  PhLP  based  on  this  model.      
Previous  studies  have  shown  that  complexes  of  PhLP  and  Gβ  were  found  that  do  not  contain  Gγ (22),  which  supports  
PhLP’s  role  in  stabilizing  Gβ  before  Gγ  can  bind  and  form  the  stable  Gβγ  dimer.      From  the  model  of  the  PhLP-­‐‑Gβ1γ1  
complex  shown  in  figure  12C&D,  it  is  clear  that  PhLP  does  not  bind  to  Gβ  like  Pdc.    The  N-­‐‑terminus  of  Pdc  is  flexible  and  
can  orient  the  rest  of  the  molecule  around  Gβγ.    In  contrast,  PhLP  is  more  rigid  and  because  of  this  I  believe  that  PhLP  and  
Gγ  are  mutually  exclusive  in  their  interaction  with  Gβ.    I  predict  that  the  key  to  PhLP’s  release  of  Gβ  can  be  found  in  the  
loop  between  H2  and  H3  indicated  by  the  white  arrows  in  figure  10  and  figure  11.    The  region  of  Gβ  that  is  critical  for  its  
interactions  with  binding  partners  is  located  on  the  top  of  the  torus  created  by  the  β  propeller  folds (24).    I  predict  that  in  
the  absence  of  Gγ,  PhLP  pinches  the  N-­‐‑terminal  α-­‐‑helix  of  Gβ  in  toward  the  hydrophobic  residues  on  the  fifth  β-­‐‑propeller  
blade  (WD5  in  Figure  4A).    This  functions  to  stabilize  Gβ  as  well  as  hold  it  in  a  position  to  readily  accept  Gγ.    The  
interaction  between  Gγ  and  Gβ  is  very  strong.    7.  Once  Gγ  comes  in  contact  with  Gβ  it  will  push  the  N-­‐‑terminal  α-­‐‑helix  of  
Gβ  away  from  WD5,  causing  PhLP  to  loosen  its  hold  on  Gβ.    8.  At  this  point  PhLP’s  affinity  for  Gβ  will  be  so  low  that  it  
will  easily  dissociate  as  Gγ  becomes  either  farnesylated  or  gernylgernylated  at  the  endoplasmic  reticulum.    Lastly,  9.  Gβγ  





Figure  12.  Revised  model  of  Gβ  biogenesis  based  on  prediction  from  the  3D  structure  generated  of  PhLP.    1.  
Nascent  Gβ  enters  the  folding  cavity  after  it  is  translated.  2.  Once  Gβ  enters  the  inner  chamber  of  CCT  it  
becomes  partially  folded,  and  3.  PhLP  binds  forming  the  tertiary  complex  and  helps  to  complete  the  folding  of  
Gβ.  When  H1  of  PhLP  binds  to  Gβ  it  also  causes  the  N-­‐‑terminal  strand  to  rotate,  exposing  residues  S18-­‐‑20.  4.  
When  these  residues  becomes  phosphorylated  by  CK2  the  charge  repulsion  causes  PhLP’s  N-­‐‑terminal  strand  
to  move  away  from  the  C-­‐‑terminal  domain,  and  6.  PhLP-­‐‑Gβ  disassociates  from  CCT.    7.  PhLP  primes  Gβ  for  
binding  to  Gγ.    Once  Gγ  binds,  it  displaces  PhLP  reducing  its  affinity  for  Gβ.    8.  PhLP’s  easily  dissociate  as  Gγ  
becomes  either  farnesylated  or  gernylgernylated  at  the  endoplasmic  reticulum  9.  Gβγ  associates  with  Gα  and  
10.  the  heterotrimeric  complex  is  trafficked  to  the  plasma  membrane.   
 16 





PhLP  is  alternatively  spliced,  resulting  in  the  loss  of  the  first  83  amino  acids  (Figure  13).    The  truncated  variant  is  
referred  to  as  PhLPSHORT  (PhLPs) (19),  and  while  full  length  PhLP  has  ubiquitous  expression,  PhLPs  is  primarily  found  in  
the  adrenal  gland (19).    This  truncation  removes  amino  acid  residues  that  are  critical  for  binding  to  Gβ.    Because  of  this,  
PhLPs  has  a  much  lower  affinity  for  Gβ  than  PhLP (20)  and  binds  Gβ  very  poorly (14, 21).  Despite  the  weak  interaction  
with  purified  Gβ,  PhLPs  can  still  interact  with  and  inhibit  CCT (10).    However,  this  interaction  has  also  been  shown  to  
inhibit  Gβγ  signaling  and  protein  expression  in  a  dominant  negative  fashion (20, 22).    Because  PhLPs  is  such  a  potent  
inhibitor  of  CCT,  is  commonly  used  as  a  tool  in  the  lab  to  study  CCT  activity.    In  cells,  PhLPs  expression  additionally  
causes  inhibition  of  Gβγ  signaling  and  a  profound  reduction  of  Gβγ  protein  expression (20, 22).    Since  PhLPs  does  not  
interact  with  Gβ  directly,  the  effects  on  G-­‐‑protein  expression  are  thought  to  be  an  indirect  consequence  of  CCT  inhibition 
(10).  In  order  to  study  the  effect  of  CCT  inhibition  on  G-­‐‑protein  signaling  in  vivo,  our  lab  created  several  lines  of  mice  that  
constitutively  expressed  PhLPs  in  rod  photoreceptors.    Photoreceptors  in  the  eye  are  classically  used  for  G-­‐‑protein  
research  due  to  the  uniquely  high  concentration  of  a  single  type  of  G-­‐‑protein  referred  to  as  transducin.  Transducin  is  a  
heterotrimeric  G-­‐‑protein  composed  of  transducin-­‐‑α  (Gtα1),  transducin-­‐‑β  (Gβ1),  and  transducing-­‐‑γ  (Gγ1)  subunits.  While  
Gβ1  and  Gγ1  are  common  to  both  rod  and  cone  photoreceptors,  Gtα1,  is  specific  to  rods.  Because  approximately  96%  of  
mouse  photoreceptors  are  rods,  using  rod  photoreceptors  allows  us  to  conduct  experiments  in  cells  enriched  in  G-­‐‑
proteins.      
Our  lab  had  previously  created  three  lines  of  transgenic  mice  that  constitutively  express  PhLPs  in  order  to  study  
the  effects  of  CCT  inhibition  in  vivo.    In  these  transgenic  mice,  expression  of  Δ1-­‐‑83PhLP  (PhLPs)  with  a  FLAG  tag  is  under  
the  control  of  a  modified  4.4  kb  rhodopsin  promoter  (Figure  14A).  Beginning  at  age  P5  in  mice,  the  rhodopsin  promoter  
becomes  active  and  PhLPs-­‐‑FLAG  is  expressed  in  the  transgenic  mice.    The  resulting  mouse  lines  were  confirmed  by  tail  
PCR  genotyping  methods  to  determine  transgenic  positive  (Tg(+)),  and  transgeneic  negative  (Tg(-­‐‑))  mice  for  each  line.    
PhLPs  protein  expression  levels  were  determined  by  immunoprecipitation  (IP)  with  α-­‐‑FLAG  antibody  and  western  
blotted  using  rabbit  anti-­‐‑FLAG  antibodies  (Figure  14B).  The  resulting  transgenic  mouse  lines  had  varying  levels  of  PhLPs  
expression.    Line  1178  is  the  “high  expressor”,  1054  is  the  “middle  expressor”,  and  1065  is  the  “low  expressor”  of  PhLPs.  
The  level  of  PhLPs  protein  expression  corresponded  to  a  progressive  loss  in  photoreceptors  as  seen  from  hemotoxylin  and  











































































Western  Blot  analysis  showed  that  PhLPs  expression  resulted  in  a  reduction  of  Gβ1,  Gγ1,  and  Gtα1  (Figure  14A).    
The  loss  of  Gβ1  can  be  explained  by  the  inhibition  of  CCT,  which  is  required  for  folding  nascent  Gβ.    Similarly,  the  loss  in  
Gγ1  is  not  surprising  because  without  Gβ  it  will  simply  be  degraded.    However,  the  effect  on  Gtα1  was  very  unexpected.    
Gtα1  protein  levels  were  so  low  that  the  fold  change  could  not  be  quantified.    The  band  seen  in  the  blot  for  Gtα1  is  non-­‐‑
specific  (Figure  14A).    Further  analysis  revealed  that  gene  expression  levels  showed  a  similar  reduction.    While  gene  
expression  of  Gβ1  (Gnb1)  and  Gγ1  (Gng1)  was  reduced  by  roughly  half,  Gtα1  (Gnat1)  mRNA  had  a  greater  than  95%  
reduction  (Figure  14B).    Currently  there  is  no  known  mechanism  to  explain  the  loss  of  Gtα1  expression.  These  findings  
represent  the  first  known  evidence  of  connecting  the  activity  of  chaperonin  CCT  to  G-­‐‑protein  gene  activity.  
The  focus  of  this  chapter  is  on  gaining  a  better  understand  of  CCT’s  role  in  the  regulation  of  G-­‐‑protein  signaling.    
We  used  a  microarray  to  show  that  the  inhibition  of  CCT  does  not  result  in  a  wide-­‐‑spread  reduction  in  gene  expression.    
Instead,  only  a  very  small  subset  of  genes  are  significantly  affected.    Because  the  expression  of  PhLPs  in  the  constitutive  
mouse  lines  cannot  be  controlled,  our  lab  also  began  developing  lines  of  transgenic  mice  that  have  inducible  expression  of  
PhLPs  (iPhLPs).    The  iPhLPs  mice  will  allow  we  to  express  PhLPs  in  mature  photoreceptors  in  order  to  determine  if  the  








One  possible  explanation  for  the  loss  of  Gtα1  at  the  protein  and  mRNA  level  due  to  PhLPs  expression  is  that  
inhibition  of  CCT  leads  to  loss  of  a  transcription  factor.    In  order  to  test  this,  the  Affymetrix  GeneChip  Whole  Transcript  
Exon  Array  was  used  to  monitor  the  changes  in  mRNA  expression  in  transgenic  mice  expressing  PhLPs  (Tg(+))  compared  
to  littermate  control  mice  (Tg(-­‐‑)).    Exon  Arrays  are  a  high-­‐‑density  microarray  platform  with  a  total  of  ~6.5  million  probes  
targeting  all  the  annotated  and  predicted  exons  in  the  genome.    A  single  gene  on  an  Exon  Array  is  assigned  a  set  of  4  core  
probes  targeted  to  each  putative  exonic  region  of  a  single  gene,  and  collectively  the  probes  representing  the  same  gene  are  
referred  to  as  a  “transcript  cluster”  (Figure  16A).    Retina  samples  were  collected  from  each  of  the  three  constitutive  mouse  
lines,  1178,  1054,  and  1065  at  P10.    For  each  line,  three  Tg+  mice  were  compared  against  Tg-­‐‑  littermate  controls  (Figure  
16B).  The  results  of  each  chip  were  first  background  subtracted  using  the  signal  from  a  set  of  37,687  genomic  and  
antigenomic  background  probes  that  are  not  matched  to  any  putative  transcript  region.    The  data  was  then  normalized  
using  GeneBASE  Probe  Effects,  which  multiplies  the  data  by  a  scaling  factor  so  that  the  median  intensity  of  all  core  probes  
in  an  array  equals  100  (Figure  17).    
Because  some  probes  respond  poorly  to  target  signals,  or  cross-­‐‑hybridize  to  non-­‐‑specific  gene  targets,  core  probes  
must  be  chosen  to  accurately  represent  changes  in  gene  expression.  Using  Probe  Select  in  the  Affy  package  of  
Bioconductor,  we  implemented  the  Li-­‐‑Wong  model  for  probe  selection (27)  The  algorithm  developed  by  Li  and  Wong  
seeks  to  identify  the  largest  subset  of  highly  correlated  probes  to  represent  a  single  gene.  They  reason  that  the  majority  of  
probes  targeting  constitutive  exons  of  a  particular  gene  will  have  a  comparable  intensity  profile  across  various  different  
tissues,  and  reflect  the  overall  mRNA  abundance  of  that  gene.    Therefore,  we  downloaded  the  mouse  exon  array  tissue  
panel  dataset  from  Affymetrix  consisting  of  11  tissues  (breast,  cerebellum,  heart,  kidney,  liver,  muscle,  pancreas,  prostate,  
spleen,  testes,  and  thyroid)  each  with  three  replicates.    For  each  gene  we  calculated  the  Pearson  correlation  coefficient  of  
the  signal  intensities  of  all  possible  pairs  of  probes  across  the  11  tissues  (a  total  of  33  samples)  and  used  that  to  perform  
average-­‐‑linkage  hierarchical  clustering,  which  is  visualized  on  a  heatmap  using  R  (Figure  18).    Hierarchical  clustering  of  
our  retina  samples  across  the  entire  tissue  panel  indicates  that  our  retina  samples  correlates  most  closely  with  retina  tissue  
samples.    When  the  retina  samples  alone  were  analyzed,  Tg+  samples  clustered  together  and  Tg-­‐‑  samples  clustered  for  
high  and  medium  expressors  (1178  and  1054).    However,  some  of  the  positive  samples  from  the  low  expressor  line  (1065)  
clustered  with  the  Tg-­‐‑  samples.    Since  the  1065  Tg+  samples  did  not  significantly  differ  from  the  Tg-­‐‑  samples,  they  were  
excluded  from  further  analysis.    This  may  be  due  to  the  fact  that  expression  level  of  this  line  is  so  low  that  retina  samples  
do  not  resemble  those  of  the  higher  expressing  lines  until  around  P21.    It  is  possible  that  samples  from  the  low  expressor  



































     Figure 18. Probe correlation across Affymetrix Mouse Exon Array Tissue Panel.  Retina samples from three positive 
and three negative mice from each of the transgenic PhLPs mouse lines at post-natal day 10 were compared to the 
mouse exon array tissue panel dataset from Affymetrix consisting of 11 tissues (breast, cerebellum, heart, kidney, 
liver, muscle, pancreas, prostate, spleen, testes, and thyroid) each with three replicates.  Hierarchical clustering was 
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H+ H-­‐ H-­‐ M-­‐ L-­‐ 
Figure	  19.	  Gene	  expression	  was	  compared	  across	  transgenic	  positive	  and	  negative	  retinal	  samples	  
from	  high	  (H),	  medium	  (M),	  and	  low	  (L)	  PhLPs	  expressor	  lines	  shown	  in	  figure	  18.	  	  Hierarchical	  
clustering	  was	  used	  to	  group	  together	  samples	  that	  show	  correlated	  gene	  expression. 
M+ H+ H+ M+ M+ M-­‐ H-­‐ M-­‐ L-­‐ L+ L-­‐ L+ L+ 
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Genes  expression  from  Tg(+)  animals  was  compared  to  Tg(-­‐‑)  controls  to  identify  genes  that  were  affected  by  
PhLPs.    The  change  in  gene  expression  was  considered  significant  if  the  p-­‐‑value  was  less  than  0.05  and  the  change  in  
expression  was  either  greater  than  1.5  or  less  than  0.5.    For  both  the  high  (1178)  and  medium  (1054)  expressor  lines,  only  
160  genes  had  a  significantly  different  expression  level  in  Tg+  samples.    When  all  of  the  Tg+  samples  were  compared  to  all  
of  the  Tg-­‐‑  samples,  only  8  genes  had  a  greater  than  1.5  fold  increase,  and  9  genes  were  decreased  by  0.5  or  more  (Table  1).    
  
Microarray  Validation  
   The  results  of  the  microarray  were  validated  by  quantitative  Real  Time  PCR  (qPCR).    The  microarray  results  
show  that  Gtα1  was  one  of  the  genes  that  had  been  significantly  decreased.  In  the  combined  analysis,  it  was  reduced  0.2  
fold,  which  is  in  agreement  with  previous  qPCR  results  (Figure  15).    Primers  for  6  genes  were  designed  for  qPCR  
validation  based  on  the  microarray  results.  Lrp4  (low  density  lipoprotein  receptor-­‐‑related  protein  4),  and  Rabgef1  (RAB  
guanine  nucleotide  exchange  factor  (GEF)  1)  were  shown  to  be  downregulated  by  the  microarray  and  were  chosen  for  
validation.    Lrp4  is  a  potential  cell  surface  endocytic  receptor,  which  binds  and  internalizes  extracellular  ligands  for  
degradation  by  lysosomes.    Rabgef1  stimulates  nucleotide  exchange  on  RAB5A  and  is  involved  in  endocytic  membrane  
fusion  and  membrane  trafficking  of  recycling  endosomes.  Additionally,  3  genes,  including  Atf3  and  two  other  genes  that  
were  shown  to  be  upregulated  based  on  microarray  results  were  chosen,  for  the  validation.    Atf3  (activating  transcription  
factor  3)  binds  the  cAMP  response  element  (CRE)  sequence  present  in  many  viral  and  cellular  promoters,  and  represses  
transcription  from  promoters  with  ATF  sites.    It  is  thought  to  repress  transcription  by  stabilizing  the  binding  of  inhibitory  
cofactors  at  the  promoter.  
Npas4  (neuronal  PAS  domain  protein  4)  is  primarily  expressed  in  the  limbic  system  and  olfactory  bulb  where  it  acts  as  a  
transcriptional  activator  to  activate  expression  of  the  drebrin  gene.    Npas4  had  a  2.4  fold  increase  in  the  high  expressor  
line  (1178),  but  was  not  found  to  be  significant  (p-­‐‑value  =  0.08)  due  to  one  low  value  in  the  medium  expressor  line  (1054).  
Eif2ak3  (eukaryotic  translation  initiation  factor  2  alpha  kinase  3)  was  chosen  because  although  the  change  in  expression  
was  found  to  be  non-­‐‑significant  in  the  microarray  (p-­‐‑value  =  0.0583),  it  had  a  2.1  fold  change  and  is  involved  in  the  
unfolded  protein  response  (UPR).  It  will  be  interesting  to  determine  if  some  of  the  observed  photoreceptor  defects  are  due  
to  UPR  from  inhibition  of  CCT.    
   The  results  from  the  qPCR  validation  are  in  general  agreement  with  the  results  of  the  microarray  (Figure  20)  
because  all  of  the  genes  show  the  same  direction  of  expression  change.    However,  there  were  some  slight  differences.    The  
change  in  Lrp4  gene  expression  was  not  found  to  be  significant  (p-­‐‑value  =  0.056)  due  to  variation  in  one  Tg+  sample.    It  is  
expected  that  with  a  larger  sample  size  (n  >  3)  the  difference  in  expression  level  will  be  significant.    Additionally,  the  
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increase  in  gene  expression  was  found  to  be  significant  for  Eif2ak3  (p-­‐‑value  =  0.009)  and  slightly  significant  for  Npas4  (p-­‐‑
value  =  0.048)  in  the  qPCR  validation  despite  have  a  non-­‐‑significant  difference  shown  in  the  microarray.    Overall,  these  
results  indicate  that  genes  from  Tg+  samples  showing  greater  than  1.5  or  less  than  2  fold  change  on  the  microarray  are  
significantly  different  from  Tg-­‐‑  samples,  and  the  UPR  may  contribute  to  some  of  the  photoreceptor  degeneration.    
  
Table  1  
P-­‐value	   Fold	  Change	   Gene	  Name	   Description	  
0.039	   0.234	   Gnat1	   guanine	  nucleotide	  binding	  protein,	  alpha	  transducing	  1	  
0.046	   0.369	   Sgcg	   sarcoglycan,	  gamma	  (dystrophin-­‐associated	  glycoprotein)	  
0.026	   0.380	   Lrp4	   low	  density	  lipoprotein	  receptor-­‐related	  protein	  4	  
0.022	   0.421	   Rabgef1	   RAB	  guanine	  nucleotide	  exchange	  factor	  (GEF)	  1	  
0.039	   0.427	   Gm9909	   predicted	  gene	  9909	  
0.035	   0.456	   Ppm1n	   protein	  phosphatase,	  Mg2+/Mn2+	  dependent,	  1N	  (putative)	  
0.039	   0.460	   Slc24a1	   solute	  carrier	  family	  24	  (sodium/potassium/calcium	  exchanger),	  member	  1	  
0.039	   0.466	   Pfkfb2	   6-­‐phosphofructo-­‐2-­‐kinase/fructose-­‐2,6-­‐biphosphatase	  2	  
0.035	   0.490	   Gucy2f	   guanylate	  cyclase	  2f	  
0.022	   0.500	   Sntb2	   syntrophin,	  basic	  2	  
0.039	   0.501	   Mmel1	   membrane	  metallo-­‐endopeptidase-­‐like	  1	  
0.045	   0.510	   Dhh	   desert	  hedgehog	  
0.039	   0.516	   Psd2	   pleckstrin	  and	  Sec7	  domain	  containing	  2	  
0.048	   0.519	   Rcvrn	   recoverin	  
0.022	   0.526	   Olfr1188	   olfactory	  receptor	  1188	  
0.040	   0.530	   Trib1	   tribbles	  homolog	  1	  (Drosophila)	  
0.046	   0.534	   Pla2r1	   phospholipase	  A2	  receptor	  1	  
0.033	   0.535	   3632451O06Rik	   RIKEN	  cDNA	  3632451O06	  gene	  
0.018	   0.541	   Dhdh	   dihydrodiol	  dehydrogenase	  (dimeric)	  
0.022	   0.549	   Tmem108	   transmembrane	  protein	  108	  
0.040	   0.555	   D730039F16Rik	   RIKEN	  cDNA	  D730039F16	  gene	  
0.039	   0.556	   Gm10394	   predicted	  gene	  10394	  
0.041	   0.557	   Kirrel	   kin	  of	  IRRE	  like	  (Drosophila)	  
0.022	   0.558	   Rpgrip1	   retinitis	  pigmentosa	  GTPase	  regulator	  interacting	  protein	  1	  
0.043	   0.582	   Trim36	   tripartite	  motif-­‐containing	  36	  
0.022	   0.595	   Xrcc6	   X-­‐ray	  repair	  complementing	  defective	  repair	  in	  Chinese	  hamster	  cells	  6	  
0.039	   0.600	   Slc25a35	   solute	  carrier	  family	  25,	  member	  35	  
0.045	   0.601	   Gldc	   glycine	  decarboxylase	  
0.041	   0.604	   Plxna2	   plexin	  A2	  
0.050	   0.607	   Impg1	   interphotoreceptor	  matrix	  proteoglycan	  1	  
0.045	   0.608	   Nxnl2	   nucleoredoxin-­‐like	  2	  
0.039	   0.609	   Polg2	   polymerase	  (DNA	  directed),	  gamma	  2,	  accessory	  subunit	  
0.045	   0.609	   Plcd3	   phospholipase	  C,	  delta	  3	  
0.039	   0.609	   Sema3f	   sema	  domain,	  immunoglobulin	  domain	  (Ig),	  short	  basic	  domain,	  secreted,	  (semaphorin)	  3F	  
0.039	   0.610	   Ric8b	   resistance	  to	  inhibitors	  of	  cholinesterase	  8	  homolog	  B	  (C.	  elegans)	  
0.043	   0.614	   Jam2	   junction	  adhesion	  molecule	  2	  
0.039	   0.614	   Gngt1	   guanine	  nucleotide	  binding	  protein	  (G	  protein),	  gamma	  transducing	  activity	  polypeptide	  1	  
0.049	   0.627	   Wdr27	   WD	  repeat	  domain	  27	  
0.040	   0.628	   Spata1	   spermatogenesis	  associated	  1	  
0.045	   0.635	   Plekhg3	   pleckstrin	  homology	  domain	  containing,	  family	  G	  (with	  RhoGef	  domain)	  member	  3	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0.039	   0.642	   Ush2a	   Usher	  syndrome	  2A	  (autosomal	  recessive,	  mild)	  homolog	  (human)	  
0.043	   0.643	   Tcfeb	   transcription	  factor	  EB	  
0.022	   0.644	   Arg2	   arginase	  type	  II	  
0.044	   0.652	   Fam149a	   family	  with	  sequence	  similarity	  149,	  member	  A	  
0.045	   0.652	   Ndrg3	   N-­‐myc	  downstream	  regulated	  gene	  3	  
0.045	   0.655	   Heg1	   HEG	  homolog	  1	  (zebrafish)	  
0.049	   0.659	   Herc3	   hect	  domain	  and	  RLD	  3	  
0.045	   0.670	   5330431K02Rik	   RIKEN	  cDNA	  5330431K02	  gene	  
0.049	   0.674	   Cc2d2a	   coiled-­‐coil	  and	  C2	  domain	  containing	  2A	  
0.043	   0.685	   Sgtb	   small	  glutamine-­‐rich	  tetratricopeptide	  repeat	  (TPR)-­‐containing,	  beta	  
0.040	   0.686	   Osbpl8	   oxysterol	  binding	  protein-­‐like	  8	  
0.046	   0.693	   Ap2a2	   adaptor	  protein	  complex	  AP-­‐2,	  alpha	  2	  subunit	  
0.049	   0.705	   Nme5	   non-­‐metastatic	  cells	  5,	  protein	  expressed	  in	  (nucleoside-­‐diphosphate	  kinase)	  
0.039	   0.707	   Apex2	   apurinic/apyrimidinic	  endonuclease	  2	  
0.039	   0.713	   Fbxo36	   F-­‐box	  protein	  36	  
0.039	   0.715	   Ikzf2	   IKAROS	  family	  zinc	  finger	  2	  
0.040	   0.717	   Mak	   male	  germ	  cell-­‐associated	  kinase	  
0.017	   0.722	   Sh3bgrl2	   SH3	  domain	  binding	  glutamic	  acid-­‐rich	  protein	  like	  2	  
0.039	   0.723	   Ceacam12	   carcinoembryonic	  antigen-­‐related	  cell	  adhesion	  molecule	  12	  
0.039	   0.723	   Epb4.1l5	   erythrocyte	  protein	  band	  4.1-­‐like	  5	  
0.040	   0.730	   Styx	   serine/threonine/tyrosine	  interaction	  protein	  
0.039	   0.742	   Glo1	   glyoxalase	  1	  
0.049	   0.743	   Dmd	   dystrophin,	  muscular	  dystrophy	  
0.039	   0.744	   Hook1	   hook	  homolog	  1	  (Drosophila)	  
0.046	   0.746	   Cdk6	   cyclin-­‐dependent	  kinase	  6	  
0.041	   0.749	   Mtap2	   microtubule-­‐associated	  protein	  2	  
0.049	   0.751	   Cacna1f	   calcium	  channel,	  voltage-­‐dependent,	  alpha	  1F	  subunit	  
0.017	   0.753	   Ppp2r5c	   protein	  phosphatase	  2,	  regulatory	  subunit	  B	  (B56),	  gamma	  isoform	  
0.039	   0.757	   6530402F18Rik	   RIKEN	  cDNA	  6530402F18	  gene	  
0.033	   0.758	   Capn7	   calpain	  7	  
0.022	   0.763	   Crlf3	   cytokine	  receptor-­‐like	  factor	  3	  
0.045	   0.768	   Top1mt	   DNA	  topoisomerase	  1,	  mitochondrial	  
0.043	   0.768	   Ect2	   ect2	  oncogene	  
0.039	   0.774	   Kctd10	   potassium	  channel	  tetramerisation	  domain	  containing	  10	  
0.040	   0.775	   Atp11b	   ATPase,	  class	  VI,	  type	  11B	  
0.026	   0.775	   Zfp322a	   zinc	  finger	  protein	  322A	  
0.039	   0.777	   Gramd1b	   GRAM	  domain	  containing	  1B	  
0.040	   0.787	   Rreb1	   ras	  responsive	  element	  binding	  protein	  1	  
0.046	   0.790	   Akr1e1	   aldo-­‐keto	  reductase	  family	  1,	  member	  E1	  
0.039	   0.791	   Trak2	   trafficking	  protein,	  kinesin	  binding	  2	  
0.045	   0.792	   Pola1	   polymerase	  (DNA	  directed),	  alpha	  1	  
0.022	   0.794	   Vps37a	   vacuolar	  protein	  sorting	  37A	  (yeast)	  
0.039	   0.796	   Cspp1	   centrosome	  and	  spindle	  pole	  associated	  protein	  1	  
0.049	   0.797	   Ypel2	   yippee-­‐like	  2	  (Drosophila)	  
0.046	   0.799	   Erlec1	   endoplasmic	  reticulum	  lectin	  1	  
0.045	   0.799	   Prtg	   protogenin	  homolog	  (Gallus	  gallus)	  
0.026	   0.804	   Zfp281	   zinc	  finger	  protein	  281	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0.039	   0.804	   Usp12	   ubiquitin	  specific	  peptidase	  12	  
0.039	   0.812	   Ofd1	   oral-­‐facial-­‐digital	  syndrome	  1	  gene	  homolog	  (human)	  
0.022	   0.816	   Sh3glb1	   SH3-­‐domain	  GRB2-­‐like	  B1	  (endophilin)	  
0.043	   0.818	   Adamts16	   disintegrin-­‐like	  and	  metallopeptidase	  (reprolysin	  type)	  with	  thrombospondin	  type	  1	  motif	  16	  
0.039	   0.826	   Msh3	   mutS	  homolog	  3	  (E.	  coli)	  
0.043	   0.831	   Zmym5	   zinc	  finger,	  MYM-­‐type	  5	  
0.039	   0.839	   Rassf8	   Ras	  association	  (RalGDS/AF-­‐6)	  domain	  family	  (N-­‐terminal)	  member	  8	  
0.039	   0.840	   Gm3435	   predicted	  gene	  3435	  
0.041	   0.841	   Rpl26	   ribosomal	  protein	  L26	  
0.046	   0.843	   Cplx2	   complexin	  2	  
0.040	   0.854	   Ep300	   E1A	  binding	  protein	  p300	  
0.040	   0.857	   Pfdn5	   prefoldin	  5	  
0.041	   0.862	   Zeb1	   zinc	  finger	  E-­‐box	  binding	  homeobox	  1	  
0.046	   0.864	   Zfp207	   zinc	  finger	  protein	  207	  
0.039	   0.867	   Itsn2	   intersectin	  2	  
0.045	   0.867	   Mtif2	   mitochondrial	  translational	  initiation	  factor	  2	  
0.049	   0.874	   Zfp106	   zinc	  finger	  protein	  106	  
0.045	   0.877	   Ank2	   ankyrin	  2,	  brain	  
0.041	   0.878	   Csnk1g1	   casein	  kinase	  1,	  gamma	  1	  
0.043	   0.878	   Kit	   kit	  oncogene	  
0.045	   0.882	   Rif1	   Rap1	  interacting	  factor	  1	  homolog	  (yeast)	  
0.046	   0.886	   Fmr1	   fragile	  X	  mental	  retardation	  syndrome	  1	  homolog	  
0.049	   0.895	   2310008H09Rik	   RIKEN	  cDNA	  2310008H09	  gene	  
0.039	   0.907	   Ncor1	   nuclear	  receptor	  co-­‐repressor	  1	  
0.045	   0.908	   Rbm27	   RNA	  binding	  motif	  protein	  27	  
0.049	   0.910	   Med14	   mediator	  complex	  subunit	  14	  
0.039	   0.911	   Nfat5	   nuclear	  factor	  of	  activated	  T-­‐cells	  5	  
0.041	   0.912	   Rb1cc1	   RB1-­‐inducible	  coiled-­‐coil	  1	  
0.039	   0.917	   Naa16	   N(alpha)-­‐acetyltransferase	  16,	  NatA	  auxiliary	  subunit	  
0.040	   0.935	   Gpatch3	   G	  patch	  domain	  containing	  3	  
0.048	   1.062	   Robo1	   roundabout	  homolog	  1	  (Drosophila)	  
0.049	   1.082	   E130112L23Rik	   RIKEN	  cDNA	  E130112L23	  gene	  
0.046	   1.097	   Fras1	   Fraser	  syndrome	  1	  homolog	  (human)	  
0.046	   1.119	   Zfp608	   zinc	  finger	  protein	  608	  
0.046	   1.120	   Lpcat3	   lysophosphatidylcholine	  acyltransferase	  3	  
0.050	   1.121	   Rhpn2	   rhophilin,	  Rho	  GTPase	  binding	  protein	  2	  
0.026	   1.123	   Phldb1	   pleckstrin	  homology-­‐like	  domain,	  family	  B,	  member	  1	  
0.040	   1.133	   Diap1	   diaphanous	  homolog	  1	  (Drosophila)	  
0.043	   1.143	   Rad50	   RAD50	  homolog	  (S.	  cerevisiae)	  
0.049	   1.152	   Nkain2	   Na+/K+	  transporting	  ATPase	  interacting	  2	  
0.039	   1.160	   Ahcyl2	   S-­‐adenosylhomocysteine	  hydrolase-­‐like	  2	  
0.022	   1.162	   Cyp1b1	   cytochrome	  P450,	  family	  1,	  subfamily	  b,	  polypeptide	  1	  
0.049	   1.175	   Slc5a11	   solute	  carrier	  family	  5	  (sodium/glucose	  cotransporter),	  member	  11	  
0.043	   1.210	   Prkcq	   protein	  kinase	  C,	  theta	  
0.043	   1.217	   Rasa2	   RAS	  p21	  protein	  activator	  2	  
0.040	   1.218	   Plcd4	   phospholipase	  C,	  delta	  4	  
0.045	   1.232	   D4Bwg0951e	   DNA	  segment,	  Chr	  4,	  Brigham	  &	  Women's	  Genetics	  0951	  expressed	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0.043	   1.234	   Prmt8	   protein	  arginine	  N-­‐methyltransferase	  8	  
0.045	   1.237	   Dnahc11	   dynein,	  axonemal,	  heavy	  chain	  11	  
0.045	   1.294	   Jph1	   junctophilin	  1	  
0.022	   1.294	   S1pr3	   sphingosine-­‐1-­‐phosphate	  receptor	  3	  
0.049	   1.295	   Slc7a2	   solute	  carrier	  family	  7	  (cationic	  amino	  acid	  transporter,	  y+	  system),	  member	  2	  
0.035	   1.296	   Lsm10	   U7	  snRNP-­‐specific	  Sm-­‐like	  protein	  LSM10	  
0.046	   1.324	   Insl5	   insulin-­‐like	  5	  
0.027	   1.333	   Gdpd2	   glycerophosphodiester	  phosphodiesterase	  domain	  containing	  2	  
0.049	   1.352	   Dnaic1	   dynein,	  axonemal,	  intermediate	  chain	  1	  
0.039	   1.355	   Mrc2	   mannose	  receptor,	  C	  type	  2	  
0.043	   1.373	   Ticam1	   toll-­‐like	  receptor	  adaptor	  molecule	  1	  
0.024	   1.382	   Insl5	   insulin-­‐like	  5	  
0.043	   1.385	   Tmod1	   tropomodulin	  1	  
0.022	   1.386	   Zmynd10	   zinc	  finger,	  MYND	  domain	  containing	  10	  
0.022	   1.392	   Pycr1	   pyrroline-­‐5-­‐carboxylate	  reductase	  1	  
0.039	   1.442	   H19	   H19	  fetal	  liver	  mRNA	  
0.045	   1.456	   Accn5	   amiloride-­‐sensitive	  cation	  channel	  5,	  intestinal	  
0.045	   1.490	   Apol7b	   apolipoprotein	  L	  7b	  
0.001	   1.603	   Abca1	   ATP-­‐binding	  cassette,	  sub-­‐family	  A	  (ABC1),	  member	  1	  
0.039	   1.648	   Efcab8	   EF-­‐hand	  calcium	  binding	  domain	  8	  
0.039	   1.727	   Klf10	   Kruppel-­‐like	  factor	  10	  
0.039	   1.889	   Wdr16	   WD	  repeat	  domain	  16	  
0.035	   1.960	   Pmp2	   peripheral	  myelin	  protein	  2	  
0.043	   3.747	   Atf3	   activating	  transcription	  factor	  3	  
0.022	   5.954	   Pdcl	   phosducin-­‐like	  
  
Gene  Ontology  Analysis  
Gene  Ontology  (GO)  analysis  was  performed  to  see  what  pathways  or  cellular  functions  were  enriched  based  on  
the  microarray  results.  Using  the  web-­‐‑based  on-­‐‑line  tool  WebGestalt  (WEB-­‐‑based  GEne  SeT  AnaLysis  Toolkit),  the  genes  
that  changed  significantly  in  Tg+  animals  were  compared  back  to  the  annotated  Affymetrix  Mouse  Exon  Array  1.0  for  
enrichment  analysis.  The  results  from  the  WebGestalt  enrichment  analysis  were  organized  into  a  “GO  Tree”,  which  is  
based  on  the  GO  DAG  (Directed  Acyclic  Graph)  in  order  to  visualize  enrichment  categories,  enriched  gene  numbers,  and  
the  statistical  significance  level  (Figure  21).  An  enriched  DAG  shows  GO  categories  with  enriched  gene  numbers  (in  red)  
and  their  non-­‐‑enriched  parents  (in  black).    Based  on  the  microarray  experiment,  a  total  of  160  genes  had  significant  
expression  changes  in  Tg+  samples  from  both  the  high  (1178)  and  medium  (1054)  expressor  lines.    Of  these  genes,  55  had  
expression    changes  by  1.5  fold  or  more.  These  genes  were  organized  into  a  GO  Tree  under  3  broad  categories  for  
biological  process,  molecular  function,  and  cellular  process.      
The  gene  categories  that  were  significantly  enriched  (p  <  0.05)  upon  PhLPs  expression  fell  under  the  ‘biological  
process’  subheading.  A  few  categories  that  were  similar  were  also  made  up  of  the  same  genes  so  All  of  the  categories  that  
most  of  the  enriched  GO  categories  identified  for  this  gene  set  could  be  placed  into  one  of  five  categories  related  to  
response  to  stimulus,  phototransduction,  eye  and  sensory  organ  development,  membrane  organization  &  endocytosis,  
and  sensory/visual  perception.      Under  the  category  ‘response  to  stimulus’  the  genes  Gngt1,  Gnat1,  and  Rcvrn  were  also  
found  in  ‘response  to  radiation’,  ‘detection  of  abiotic  stimulus’,  ‘detection  of  external  stimulus’,  ‘detection  of  stimulus’,  
‘response  to  light  stimulus’,  ‘response  to  abiotic  stimulus’,  and  ‘phototransduction’.  Similarly,  the  same  three  genes,  
Rpgrip,  Gngt1,  and  Gnat1,  make  up  the  categories  ‘eye  photoreceptor  development’,  ‘photoreceptor  cell  differentiation’,  
‘photoreceptor  cell  development’,  ‘eye  development’,  ‘neuron  development’.    In  addition,  the  genes  Lrp4,  Abca1,  Pla2r1,  
and  Rabgef1  make  up  the  ‘endocytosis’  category  as  well  as  ‘membrane  invagination’,  ‘vesicle-­‐‑mediated  transport’,  and  
‘membrane  organization’.    Lastly,  the  ‘sensory  perception  of  light’  and  ‘visual  perception’  categories  were  made  up  of  the  
genes  Pdcl,  Rpgrip1,  Rcvrn,  Ush2a,  Gucy2f,  and  Gnat1.    Although  ‘spermatid  development’  was  listed  as  a  significantly  
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enriched  category,  it  is  made  up  of  only  two  genes,  Dhh  and  Prm1.  However,  the  significant  upregulation  in  gene  
expression  of  Prm1  (protamine  1)  that  was  shown  in  the  microarray  analysis  may  just  be  an  artifact  because  the  
polyadenylation  sequence  of  the  transgene  was  derived  from  Prm1.    Further  validation  tests  using  qPCR  have  indicated  
that  the  levels  of  Prm1  do  not  change  significantly.  
What  is  noticeably  absent  from  the  enrichment  analysis  is  an  involvement  of  genes  in  apoptotic  or  the  UPR.    Since  
the  minimum  number  of  genes  required  to  show  enrichment  in  a  single  category  was  only  set  to  2,  it  is  unlikely  that  these  
pathways  play  a  role  in  CCT’s  connection  to  G-­‐‑protein  expression.  A  few  individual  genes  that  appeared  in  many  
categories  of  the  GO  Tree  analysis  were  Lrp4,  Rabgef1,  Rcvrn,  Ush2a,  and  Rpgrip1.    Lrp4  (low  density  lipoprotein  
receptor-­‐‑related  protein  4)  and  Rabgef1  (RAB  guanine  nucleotide  exchange  factor  (GEF)  1)  are  both  involved  in  
membrane  organization  and  invagination,  and  Lrp4  is  also  involved  in  cellular  development.  The  Rcvrn  (recoverin)  gene  
encodes  a  member  of  the  recoverin  family  of  neuronal  calcium  sensors  and  is  thought  to  prolong  the  termination  of  the  
phototransduction  cascade  in  the  retina  by  blocking  the  phosphorylation  of  photo-­‐‑activated  rhodopsin.  Two  very  
interesting  genes  are  Ush2a  (Usher  syndrome  2A  homolog)  and  Rpgrip1  (retinitis  pigmentosa  GTPase  regulator  
interacting  protein  1),  which  are  both  involved  in  photoreceptor  development,  visual  perception,  and  cell  projection.    
Usher  syndrome  is  a  genetic  disorder  that  is  characterized  by  deafness  and  progressive  loss  of  vision.    The  three  different  
types  of  Usher  syndrome  are  thought  to  be  responsible  for  3  percent  to  6  percent  of  all  childhood  deafness  and  about  50  
percent  of  deaf-­‐‑blindness  in  adults.    Interestingly,  the  loss  of  vision  is  due  to  the  eye  disease,  retinitis  pigmentosa  (RP),  
which  causes  photoreceptor  degeneration.    Although  Ush2a  expression  was  only  increased  by  0.64  fold  (Table  1),  it  is  
tempting  to  make  a  connection  between  CCT  inhibition  and  gene  expression  changes  that  are  seen  in  a  progressive  eye  
disease.    Overall,  these  results  support  the  role  of  CCT  in  G-­‐‑protein  expression  and  signaling  because  when  CCT  is  
inhibited  by  PhLPs,  the  genes  involved  in  visual  processing  and  photoreceptor  development  are  significantly  impacted.      
  
.  
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Inducible  expression  of  PhLPs  (iPhLPs)  
   In  young  mice,  the  expression  of  rhodopsin  occurs  around  age  P5  and  triggers  the  development  of  rod  
photoreceptor  outer  segments.    Inhibition  of  CCT  during  this  critical  period  could  affect  specific  molecular  or  signaling  
events  related  to  development.  A  major  limitation  of  the  high  (1178),  medium  (1054),  and  low  (1065)  expressor  lines  is  the  
inability  to  control  PhLPs  expression.    Expression  of  PhLPs  in  these  lines  began  at  P10  with  the  expression  of  rhodopsin.    
Because  we  could  only  identify  the  transcriptional  CCT  feedback  in  the  underdeveloped  photoreceptors  of  neonatal  mice  
constitutively  expression  PhLPs  we  couldn’t  determine  whether  the  inhibition  of  CCT  might  cause  development  changes.  
To  overcome  this  limitation,  transgenic  models  with  the  regulated  tetracycline-­‐‑dependent  PhLPs  expression  have  been  
developed  in  our  laboratory  in  order  to  study  the  effect  of  CCT  suppression  on  the  Gtα1  gene  (Gnat1)  activity  in  retinas  of  
adult  mice.  
We  have  developed  six  lines  of  transgenic  mice  that  have  tetracyclin-­‐‑inducible  PhLPs  expression  (iPhLPs)  to  
allow  us  to  study  the  effect  of  CCT  suppression  on  Gnat1  activity  in  retinas  of  adult  mice.  These  mice  were  generated  by  
crossing  transgenic  TRE-­‐‑Tight-­‐‑Δ1-­‐‑83PhLP-­‐‑FLAG  mice  (expressing  PhLPs),  with  mice  containing  a  reverse  tetracycline-­‐‑
dependent  transactivator  (rtTA)  under  the  control  of  an  opsin  promoter.  The  result  of  this  cross  is  a  mouse  line  carrying  
both  the  TRE-­‐‑Tight-­‐‑Δ1-­‐‑83PhLP-­‐‑FLAG  as  well  as  the  rtTA  transgene  (Figure  22A).  After  age  P5  rtTA  is  continuously  
produced  in  retinal  photoreceptor  cells  where  the  opsin  promoter  is  active.    In  order  for  the  TRE-­‐‑Tight  promoter  to  
become  active,  it  must  be  bound  by  both  rtTA  and  tetracycline.  Therefore,  in  this  inducible  model  administration  of  the  
tetracycline  analog,  doxycycline,  drives  PhLPs  expression  specifically  in  photoreceptor  cells.  
Several  lines  of  iPhLPs  were  generated  and  tested  for  PhLPs  expression  by  FLAG  immunoprecipitation  (IP)  and  
western  blotting  for  α-­‐‑FLAG.    Out  of  these  lines,  two  lines  (line  2339  and  2347)  were  chosen  for  further  experimentation  
because  they  had  the  highest  level  of  PhLPs  expression.    Mice  from  these  lines  were  genotyped  to  identify  individuals  
that  were  positive  for  the  iPhLPs  transgene.    These  PhLPs  positive  mice  were  then  given  doxycycline  to  induce  expression  
of  PhLPs  in  retinal  photoreceptors.    Initially,  doxycycline  was  administered  through  drinking  water  at  either  1.0  or  10  
mg/ml  for  10  days,  but  there  was  some  variability  in  PhLPs  induction.    In  order  to  reduce  the  variability,  all  mice  were  
given  10  mg/ml  doxycycline  +  50  mg/ml  sucrose  in  their  drinking  water  for  1,  3,  or  9  days  (figure  22B  upper  panel).    
Because  PhLPs  expression  remained  highly  variable  and  occurred  with  low  frequency,  0.1  ml  doxycycline  (10  mg/ml)  was  
administered  by  intraperitoneal  injection  every  24hrs  for  two  days  (figure  22B,  lower  panel).    Despite  the  efforts  to  
standardize  the  amount  of  doxycycline  that  each  animal  received,  the  individual  variability  in  PhLPs  expression  even  
among  
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littermates  remained  high.  
In  order  to  test  whether  
PhLPs  induced  CCT  inhibition  
in  adult  mice  has  the  same  
effect  on  G-­‐‑protein  levels  in  
mice  at  P10,  the  levels  of  Gnat1,  
Gnb1,  and  Gng1  were  
measured  in  adult  iPhLPs  mice.    
iPhLPs  positive  mice  mice  were  
identified  by  genotyping  and  
given  0.1  ml  doxycycline  (10  
mg/ml)  by  intraperitoneal  
injection  every  24hrs  for  five  
days.  After  the  induction  
period,  mice  were  sacrificed  
and  one  retina  was  used  to  
identify  mice  that  expressed  
PhLPs  while  the  other  eye  from  
the  same  mouse  was  used  to  
measure  G-­‐‑protein  levels.    Even  
after  5  days  of  doxycycline  
injects  not  all  of  the  animals  that  were  identified  as  PhLPs  positive  by  genotyping  expressed  a  high  enough  amount  of  
PhLPs  to  be  detectable  by  IP.    The  mice  that  were  PhLPs  positive  but  did  not  express  sufficient  PhLPs,  referred  to  as  “non-­‐‑
expressors”,  were  used  as  a  negative  control  (N/Exp  in  figure  23).    The  results  shown  in  figure  23  compare  the  change  in  
expression  of  Gtα1,  Gβ1,  and  Gγ1  normalized  to  HPRT  from  the  two  iPhLPs  lines  to  non-­‐‑expressors  from  2347  (n  =  3).  Gβ1  
and  Gγ1  levels  do  not  change  significantly  compared  to  control.    However,  Gtα1  had  a  9  fold  reduction  in  the  2339  line  and  
a  6  fold  reduction  in  the  2347  line.    The  results  from  this  set  of  experiments  is  in  general  agreement  with  the  results  from  
the  constitutive  line,  indicating  that  the  reduction  of  G-­‐‑protein  levels  by  CCT  inhibition  is  not  dependent  on  a  





The  objective  of  this  project  has  been  to  investigate  the  role  of  CCT  in  the  biosynthesis  and  regulation  of  
heterotrimeric  G  proteins.    I  set  out  to  build  upon  the  initial  data  from  our  lab  indicating  that  the  inhibition  of  CCT  affects  
Gtα1,  Gβ1,  and  Gγ1  at  the  protein  level  as  well  as  the  mRNA  transcript  level.    The  inducible  PhLPs  (iPhLPs)  mouse  lines  
were  generated  in  an  attempt  to  find  a  connection  between  CCT  and  G-­‐‑protein  expression  that  is  dependent  on  a  
developmental  process.    Despite  the  low  frequency  of  PhLPs  induction  and  the  high  variability  among  individual  animals  
I  was  able  to  complete  one  set  of  experiments.    Because  the  reduction  in  G-­‐‑protein  levels  from  these  adult  animals  initially  
appears  to  be  the  same  as  those  seen  in  younger  mice  from  the  constitutive  lines,  it  appears  that  mature  photoreceptors  as  
just  as  susceptible  as  developing  photoreceptors.    However,  due  to  the  high  variability  in  PhLPs  expression,  this  
experiment  will  need  to  be  repeated.  
PhLPs  is  a  potent  inhibitor  of  CCT,  which  is  responsible  for  folding  a  wide  variety  of  proteins  with  many  diverse  
functions.    Based  on  this,  one  might  think  that  the  most  significant  effect  of  PhLPs  expression  would  be  triggering  of  the  
unfolded  protein  response  (UPR).  However,  the  results  of  the  microarray  and  Gene  Ontology  (GO)  analysis  have  
indicated  that  this  is  not  the  case.    Very  few  genes  are  significantly  affected  by  the  inhibition  of  CCT  by  PhLPs  based  on  
the  microarray  results.    Only  160  genes  had  changes  in  gene  expression  that  were  significant  different  in  either  the  high  
(1178)  or  medium  (1054)  expressor  lines  of  mice  constitutively  expressing  PhLPs.    Out  of  these  160  genes  only  9  genes  had  
expression  levels  that  were  decreased  by  more  than  2  fold  or  increased  more  than  1.5  fold.    Collectively  these  experiments  
indicate  that  CCT  plays  an  essential  role  in  the  visual  process.  The  genes  that  are  most  heavily  impacted  by  its  inhibition  
are  involved  in  visual  perception  or  cellular  organization.    Gnat1  stood  out  in  the  microarray  results  because  it  had  the  
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largest  decrease  in  mRNA  expression.    Despite  the  fact  that  these  results  were  strikingly  specific,  they  still  offered  no  
direct  connection  between  CCT  and  Gα.      
In  the  future,  it  may  be  prudent  to  design  experiments  that  connect  the  resulting  changes  in  gene  expression  due  
to  CCT  inhibition  with  loss  of  photoreceptor  cells.      It  will  be  interesting  to  see  if  inducing  PhLPs  in  adult  mice  will  lead  to  
the  same  degree  of  photoreceptor  death  that  was  seen  in  the  constitutive  lines  of  younger  animals.    Because  many  of  the  
same  genes  participate  in  numerous  biological  processes  as  indicated  by  the  GO  analysis,  it  is  possible  that  the  Gα  loss  
due  to  PhLPs  expression  causes  more  significant  cell  death  in  developing  photoreceptors  than  in  adult  photoreceptors.    
This  could  be  tested  by  doing  functional  experiments  such  as  an  electroretinogram  (ERG)  slides  and  histology  
experiments  using  photoreceptors  of  inducible  mice  to  support  the  previous  findings.    This  may  lead  to  discovering  a  
connection  between  CCT  and  Gα.  
  




Generation  of  PhLPs  Transgenic  Mice  
Three  lines  of  transgenic  mice  were  generated (28)to  constitutively  express  PhLPs  in  rod  photoreceptor  cells.  To  
prepare  the  dominant  negative  form  of  phosducin-­‐‑like  protein  lacking  the  first  83  amino  acids  and  containing  C-­‐‑terminal  
FLAG  tag,  total  RNA  was  first  isolated  from  the  retina  of  a  129/SV  mouse  using  the  Absolutely  RNA  Miniprep  Kit  
(Stratagene,  La  Jolla,  CA),  and  the  RNA  was  reverse  transcribed  using  the  mouse  PhLP  gene-­‐‑specific  RT  primer  5’-­‐‑ACT  
AAA  TGA  GAC  TAC  AA  with  the  AccuScript  High  Fidelity  1st  Strand  cDNA  Synthesis  Kit  (Stratagene;  #200820).  A  PCR,  
using  the  PfuUltra  Hotstart  PCR  Master  Mix  (Stratagene;  #600630),  was  used  to  amplify  the  coding  sequence  of  PhLP  from  
the  subsequent  cDNA,  beginning  with  the  84th  codon,  thereby  creating  Δ1-­‐‑83PhLP  (PhLPs).  At  the  same  time,  a  SalI  site  and  
a  Kozak  sequence  (GCCACCATGG)  were  added  to  the  5’  end,  and  a  FLAG  sequence,  followed  by  a  BamHI  site  and  two  
new  stop  codons,  were  added  to  the  3’  end  of  PhLPs.  Because  the  84th  codon  of  PhLP  happens  to  be  ATG,  no  additional  
start  codon  was  needed.  The  following  primers  were  used  during  PCR  to  achieve  these  changes:  forward  primer  5’-­‐‑GAG  
AGT  CGA  CGC  CAC  CAT  GGA  GCG  GCT  GAT  CAA  AAA  G  and  reverse  primers  5’-­‐‑  CTT  GTC  ATC  GTC  GTC  CTT  
GTA  ATC  ATC  TAT  TTC  CAG  ATC  GCT  GTC  TTC  and  5’-­‐‑  GCC  TGG  ATC  CCT  ACT  ACT  TGT  CAT  CGT  CGT  CCT  
TGT  AAT  C.  Two  separate  PCR  reactions  were  performed  to  keep  the  primers  from  getting  too  large.  Both  reactions  were  
done  using  the  same  forward  primer,  whereas  the  first  reaction  was  done  with  the  first  reverse  primer  shown  and  the  
second  reaction  with  the  second  reverse  primer  shown.  After  each  reaction,  PCR  products  were  run  on  an  agarose  gel,  
and  the  appropriate  product  band  cut  out  and  purified  with  the  Wizard  SV  Gel  and  PCR  Clean-­‐‑Up  System  (Promega,  
Madison,  WI;  A9281).  The  final  PCR  product  was  cloned  into  the  pBAM4.2  vector  containing  a  4.4  kb  mouse  rhodopsin  
promoter  and  a  mouse  protamine  I  polyadenylation  sequence (29).  Briefly,  both  the  final  PCR  product  and  the  pBAM4.2  
vector  were  digested  with  SalI  and  BamHI  restriction  endonucleases,  gel  purified,  and  ligated  so  the  Kozak-­‐‑  PhLPs-­‐‑FLAG  
sequence  would  be  inserted  following  the  mouse  rhodopsin  promoter  and  before  the  mouse  protamine  I  poly(A)  
sequence,  creating  pRhop4.4k-­‐‑  PhLPs.  The  integrity  of  the  construct  was  confirmed  by  sequence  analysis,  and  the  final  
transgene  (4.4  kb  rhodopsin  promoter-­‐‑Kozak-­‐‑  PhLPs-­‐‑FLAG-­‐‑MPI  poly(A))  was  removed  from  pRhop4.4k-­‐‑  PhLPs  by  
digestion  with  restriction  endonucleases  KpnI  and  SpeI,  gel  purified,  and  used  for  mouse  pronuclear  injections  at  the  
WVU  Transgenic  Animal  Core  Facility.  Founder  mice  carrying  PhLPs-­‐‑FLAG  were  selected  by  PCR  genotyping  of  tail  
genomic  DNA  using  the  following  primers:  forward  primer  5’-­‐‑GTG  AAT  TGA  TTG  GCA  ATT  TTG  TTC  G  and  reverse  
primer  5’-­‐‑  ACT  ACT  TGT  CAT  CGT  CGT  CC.    
Three  lines  of  mice  constitutively  producing  PhLPs  were  generated  and  designated  1178,  1054,  and  1065.  Protein  
expression  of  PhLPs-­‐‑FLAG  in  the  retinas  was  confirmed  and  quantified  by  immunoblotting  using  anti-­‐‑FLAG  antibody.    
The  1178  line  had  highest  expression  and  is  referred  to  as  the  high  expressor,  1065  is  the  low  expressor,  and  1054  is  the  
middle  expressor  of  PhLPs.    Colonies  were  established  and  maintained  by  crossing  PhLPs-­‐‑FLAG  mice  with  129/SV  mice  
(Charles  River,  Wilmington,  MA).  All  experiments  involving  animals  were  performed  according  to  the  procedures  
approved  by  the  Animal  Care  and  Use  Committees  of  West  Virginia  University  and  University  of  Minnesota.  
  
Generation  of  the  inducible  PhLPs-­‐‑i  transgenic  mice    
In  order  to  control  the  onset  of  PhLPs  expression  and  CCT  suppression,  we  have  generated  transgenic  mice  with  
the  ability  to  induce  expression  of  PhLPs  (PhLPs-­‐‑i)  using  a  reverse  tetracycline-­‐‑dependent  transactivator  (rtTA).  
Transgenic  TRE-­‐‑Tight-­‐‑PhLPs-­‐‑FLAG  mice  were  generated  by  adding  a  commercial  tetracycline  responsive  promoter,  TRE-­‐‑
Tight  (Clontech),  to  a  mouse  PhLPs  cDNA  containing  a  C-­‐‑terminal  FLAG  tag.  These  transgenic  TRE-­‐‑Tight-­‐‑PhLPs-­‐‑FLAG  
were  crossed  with  opsin-­‐‑rtTA  mice  (Tg(opsin-­‐‑rtTA)  +/+),  generously  provided  by  Drs.  Zack  and  Campochiaro  (Johns  
Hopkins  University).    Using  this  model,  six  transgenic  PhLPs-­‐‑i  lines  have  been  generated  at  the  WVU  Transgenic  Animal  
Core  Facility.    Because  the  reverse  tetracycline-­‐‑dependent  transactivator  (rtTA)  is  under  the  control  of  an  opsin  promoter,  
progeny  of  this  cross  express  rtTA  in  photoreceptors.  Following  administration  of  the  stable  tetracycline  analog,  
doxycycline,  the  TRE-­‐‑Tight  promoter  will  drive  expression  of  PhLPs-­‐‑FLAG  in  photoreceptors.    Doxycycline  was  
administered  through  drinking  water  (5  µμg/ml  doxycycline  +  50  µμg/µμl  sucrose  for  10  days)  and  interperitoneal  injection  
(0.1  ml  twice  a  day  for  5  days),  and  was  optimized  by  monitoring  PhLPs  protein  levels  through  immunoprecipitation  (IP)  
and  western  blot  of  α-­‐‑FLAG.    In  two  of  the  lines,  progeny  positive  for  both  transgenes  (Tg(PhLPs-­‐‑i)+/-­‐‑;  Tg(opsin-­‐‑rtTA)  +/-­‐‑)    
express  amounts  of  PhLPs  comparable  to  the  1054  (medium  PhLPs  expressor)  constitutive  line.  Both  models  allow  
expression  of  PhLPs  in  mature  photoreceptors.  
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Immunoprecipitation  and  Western  Blot  
Single  retinas  were  homogenized  by  short  ultrasonic  pulses  in  0.2  ml  of  RIPA  buffer  (Sigma;  R0278).  Cell  
membranes  and  insoluble  parts  were  cleared  by  centrifugation,  and  supernatant  was  incubated  with  10  µμl  of  anti-­‐‑FLAG  
M2-­‐‑Agarose  (Sigma;  A2220),  for  1  h  at  room  temperature.  Beads  were  washed  3  times  with  0.2  ml  of  RIPA  buffer.    
Proteins  bound  to  the  FLAG-­‐‑Agarose  beads  were  eluted  using  1%  USB  (20  mM  Tris-­‐‑HCl,  pH  7.5,  8  M  urea,  4.5%  SDS),  
and  loaded  onto  a  10%  Agarose  gel.    After  the  bands  were  separated,  they  were  transferred  to  an  Immobilon-­‐‑FL  PVDF  
membrane  (Millipore)  in  Towbin  buffer  containing  25  mM  Tris,  192  mM  Glycine,  and  10%  (v/v)  methanol  for  1.5  h  at  0.25  
A.    
Western  Blot  –  After  transfer,  the  membrane  was  blocked  with  Odyssey  non-­‐‑mammalian  protein  blocking  buffer  
(LI-­‐‑COR;  927-­‐‑40000)  for  10  minutes  at  room  temperature.  The  membrane  was  then  probed  with  rabbit  α-­‐‑FLAG  (Rockland;  
600-­‐‑401-­‐‑383)  at  1:5,000  dilution  in  1%  PBS  (Phosphate  Buffered  Saline  solution,  Fisher;  BP399-­‐‑4)  with  0.01%  Tween  20  
(Sigma;  P7949)  for  1  hour  at  room  temperature.    Before  the  secondary  antibody  was  applied,  the  membrane  was  washed  
three  times  with  1%  PBS  with  0.01%  Tween  20  for  five  minutes.    Goat-­‐‑anti  rabbit  IgG  Alexa  Fluor  680  (Invitrogen;  A21109)  
was  then  applied  at  1:50,000  dilution  in  1%  PBS  with  0.01%  Tween  20  for  45  minutes  at  room  temperature.  The  membrane  
was  washed  three  times  with  1%  PBS  with  0.01%  Tween  20  for  five  minutes  before  bands  were  visualized  using  an  
Odyssey  Infrared  Imaging  System  (LI-­‐‑COR  Biosciences,  Lincoln,  NE)  according  to  the  manufacturer’s  protocols.  
  
RNA  Isolation  
Single  retinas  were  collected  from  the  constitutive  PhLPs  mouse  lines  at  postnatal  day  10  and  11  (P10  and  P11),  
while  samples  from  the  inducible  PhLPs  (iPhLPs)  mouse  lines  were  taken  from  adult  animals  (8–10  weeks  of  age).  Total  
RNA  was  isolated  from  each  of  these  retinas  using  the  Absolutely  RNA  Miniprep  kit  (Agilent  Technologies),  according  to  
the  manufacturer’s  protocol  for  small  samples,  and  including  two  DNAse  treatments.  The  final  concentration  of  total  
RNA  (A260)  was  quantified  using  a  NanoDrop  ND-­‐‑1000  spectrophotometer  (NanoDrop  Technologies).    
  
qRT-­‐‑PCR  
Using  a  two-­‐‑step  qRT-­‐‑PCR  process,  cDNA  from  each  retina  was  generated  from  5ng  of  total  RNA  using  the  
AffinityScript  QPCR  cDNA  Synthesis  kit  (Agilent  Technologies)  and  oligo(dT)  primers.    No  template  reactions  served  as  
negative  controls.  qRT-­‐‑PCR  experiments  were  performed  in  triplicate  with  0.5ng  of  cDNA  using  the  Brilliant  II  SYBR®  
Green  QPCR  Master  Mix  (Agilent  Technologies),  reference  dye,  and  200  nM  of  each  primer.    Reactions  were  incubated  at  
950C  for  10  min,  and  then  cycled  27X  at  950C  for  30  s,  550C  for  60  s,  and  720C  for  30  s  using  a  Stratagene  Mx3000P™  real-­‐‑
time  PCR  system.    A  melting  curve  analysis  was  added  at  the  end  to  verify  a  single  product  from  each  reaction,  and  the  
fluorescence  was  recorded  during  every  QPCR  cycle  at  both  the  annealing  step  (550C)  and  the  extension  step  (720C).    
Fluorescence  values  were  analyzed  using  MxPro  QPCR  Software  version  4.10  and  amplification  thresholds  were  
normalized  to  those  of  GAPDH.      
Primers  for  mouse  Gnat1,  Gnb1,  and  Gngt1  (Table  1)  were  designed  using  GenBank  mouse  mRNA  sequences  and  
PrimerQuest  software  (http://scitools.idtdna.com/Primerquest/)  and  selected  to  amplify  products  crossing  exon-­‐‑exon  
boundaries.    The  primers  were  synthesized  and  HPLC-­‐‑purified  by  Integrated  DNA  Technologies  (IDT)  (Coralville,  IA).    
Primer  were  optimized  for  each  reaction  prior  to  running  qRT-­‐‑PCR  experiments.  The  primer  sequences  used  were  as  
follows:    
    
   Forward  5’-­‐‑3’   Reverse  5’-­‐‑3’  
Gnat1   TGCCATCATCTACGGCAACACTCT   CTTGGGCATTGTGCCTTCCTCAAT  
Gnb1   AGAATCCAAATGCGGACCAGGAGA   ACCACAGGCCACATAATTCCCAGA  
Gng1   TGCCAGTGATCAACATCGAAGACC   TCACACAGCCTCCTTTGAGTTCCT  




Affymetrix  GeneChip  Whole  Transcript  (WT)  Sense  Targeting  Labeling  Assay  was  used  on  Exon  Array  
GeneChips.    Whole  retinas  from  PhLPs  positive  transgenic  animals  (Tg(+))  were  compared  to  PhLPs  negative  littermate  
controls  (Tg(-­‐‑))  for  each  of  the  three  constitutive  lines  (1178  “high”  expressor,  1054  “medium”  expressor,  and  1065  “low”  
expressor)  in  triplicate  on  individual  chips  for  a  total  of  18  arrays.  The  microarray  chips  were  analyzed  using  a  GeneChip  
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Scanner  3000  7G  Plus  (Affymetrix).    The  resulting  files  generated  from  the  Affymetrix  chips  were  analyzed  in  R  using  
Bioconductor.    Background  subtraction  and  normalization  were  performed  using  GeneBASE  (Genelevel  Background  
Adjusted  Selected  probe  Expression).    Briefly,  the  fluorescence  signals  from  antigenomic  background  probes  were  
subtracted  from  core  probes.    The  background-­‐‑adjusted  core  probes  were  then  normalized  using  a  simple  multiplicative  
scaling  factor  so  that  the  median  value  equals  100.      
Gene  expression  indexes  for  each  gene  were  computed  using  the  Li-­‐‑Wong  model (27, 30)  via  the  affy  package  of  
Bioconductor  (http://www.bioconductor.org/).  The  Li-­‐‑Wong  algorithm  seeks  to  identify  the  core  probes  that  best  reflect  
the  overall  mRNA  abundance  by  identifying  the  largest  subset  of  highly  correlated  probes  that  correspond  to  exons  
across  various  mouse  tissues.  For  this  purpose,  our  samples  were  compared  to  the  Mouse  Exon  1.0  ST  Array  tissue  panel  
dataset  (http://www.affymetrix.com/support/technical/sample_data/exon_array_data.affx)  consisting  of  11  mouse  tissues  
(breast,  cerebellum,  heart,  kidney,  liver,  muscle,  pancreas,  prostate,  spleen,  testes,  and  thyroid)  each  with  three  replicates.  
For  each  transcript  cluster,  we  calculated  the  Pearson  correlation  coefficient  of  the  signal  intensities  of  all  possible  pairs  of  
probes  across  the  11  tissues  (a  total  of  33  samples).  We  visualized  the  correlation  matrix  of  the  probe  intensities  as  a  
heatmap  using  R  (http:///www.r-­‐‑project.org).    
Differences  in  gene  expression  between  Tg(+)  and  Tg(-­‐‑)  were  calculated  using  a  two-­‐‑tailed  student’s  t-­‐‑test.    
Changes  were  considered  significant  if  the  p-­‐‑value  was  less  than  0.05  and  the  fold  change  increased  or  decreased  by  more  
than  2  fold.  Gene  Ontology  (GO)  analysis  of  the  annotated  gene  list  was  performed  using  the  web-­‐‑based  on-­‐‑line  tool  
WebGestalt  (WEB-­‐‑based  GEne  SeT  AnaLysis  Toolkit).  A  list  of  the  Entrez  Gene  ID  numbers  of  differentially  expressed  
genes  were  uploaded  to  http://bioinfo.vanderbilt.edu/webgestalt/  and  analyzed  using  the  entire  annotated  dataset  as  a  
reference  set  for  enrichment  analysis.    A  hypergeometric  statistical  method  was  used  with  bonferroni  adjustment.  The  
significance  level  was  set  at  0.05  and  the  minimum  number  of  genes  per  category  was  set  at  2.      
Genes  were  validated  using  qPCR  as  stated  above.    Using  the  Stratagene  MX3000P  thermocycler,  reactions  were  
incubated  at  950C  for  10  min,  and  then  cycled  for  40  cycles  at  950C  for  30  s,  and  640C  for  30  s.    Products  were  run  on  an  
agarose  gel  to  check  for  specificity.  
  
   Forward  5’-­‐‑3’   Reverse  5’-­‐‑3’  
Sgcg   AAAGTGGGTGCCCAGATGGTAGAA   AAACCCACAGTTTCAGCATCCAGC  
Lrp4   TGACAGCAGTGACGAAAGTCCACA   TTACATCCTGGCACGTTCTCCCAT  
Rabgef1   ACCTTCCACAAGACAGGCCAAGAA   ACTTTCTCTGGAGGCACTTTCCCA  
Eif2ak3   AGCCAGAGGTGTTTGGGAACAAGA   ACCGAAGTTCAAAGTGGCCAACAC  
Npas4   TCAGGCTGAAATGGTGGTGAGACT   TGAAGTCCAGCTCTTTGGAGGGTT  
Atf3   GTCAGTTACCGTCAACAACAGACC   GCAGGCACTCTGTCTTCTCC  




3D  structures  were  obtained  from  the  Research  Collaboratory  for  Structural  Bioinformatics  (RCSB)  Protein  
Databank  (PDB)  http://www.rcsb.org.    Crystallographic  coordinates  for  the  two  phosducin  (Pdc)  template  molecules  were  
based  on  published  crystal  structures  (PDB  entry  1B9X,  and  2TRC).  The  sequence  for  mouse  PhLP  was  taken  from  the  
SwissProt  database  (accession  number  Q9DBX2).    Sequence  alignment  and  generation  of  a  3D  model  for  PhLP  was  
accomplished  using  INSIGHTII/CONSENSUS  software  (Accelrys,  San  Diego,  CA,  USA)  v.2005  on  a  Silicon  Graphics  
workstation.    All  simulations  were  conducted  at  the  Computational  Chemistry  and  Molecular  Modeling  Lab  as  part  of  the  
WVU  Health  Science  Center.    
   Sequence  alignment  –  Sequence  alignment  and  the  generation  of  a  3D  model  of  PhLP1  was  accomplished  using  the  
HOMOLOGY  module  of  INSIGHTII  (Accelrys,  San  Diego,  CA,  USA).    The  sequences  for  the  two  Pdc  template  molecules  
were  first  aligned  by  identifying  structurally  conserved  regions  (SCRs).  SCRs  are  based  on  root-­‐‑mean-­‐‑square  (rms)  
deviation  of  the  backbone  and  were  determined  by  maximizing  the  scores  from  Dayhoff’s  mutation  matrix  and  the  
Engleman  and  Steitz  hydrophobicity  index.    After  SCRs  for  the  template  molecules  were  assigned,  PhLP  was  then  aligned  
to  the  template  sequence  using  manual  pairwise-­‐‑alignment.    Secondary  structural  elements  were  predicted  based  on  
primary  amino  acid  sequences  using  the  web-­‐‑based  online  tool,  PredictProtein  http://www.predictprotein.org/.    The  
locations  of  each  predicted  secondary  structural  element  on  PhLP  was  then  compared  to  those  on  Phosducin  based  on  the  
sequence  alignment.  
 36 
   Generating  the  PhLP  structure  –  After  the  SCRs  were  determined,  coordinates  of  the  model  were  assigned  based  on  
distance  geometry  calculations  through  the  CONSENSUS  module  of  INSIGHTII.  The  PhLP  structure  that  was  generated  
was  refined  using  the  BIOPOLYMER  module  of  INSIGHTII  to  achieve  the  lowest  energy  conformation.    
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